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Abstract
Mutations in OPA1 cause autosomal dominant optic atrophy (DOA)
as well as DOA+, a phenotype characterized by more severe neuro-
logical deficits. OPA1 deficiency causes mitochondrial fragmenta-
tion and also disrupts cristae, respiration, mitochondrial DNA
(mtDNA) maintenance, and cell viability. It has not yet been estab-
lished whether phenotypic severity can be modulated by genetic
modifiers of OPA1. We screened the entire known mitochondrial
proteome (1,531 genes) to identify genes that control mitochon-
drial morphology using a first-in-kind imaging pipeline. We identi-
fied 145 known and novel candidate genes whose depletion
promoted elongation or fragmentation of the mitochondrial
network in control fibroblasts and 91 in DOA+ patient fibroblasts
that prevented mitochondrial fragmentation, including phos-
phatidyl glycerophosphate synthase (PGS1). PGS1 depletion
reduces CL content in mitochondria and rebalances mitochondrial
dynamics in OPA1-deficient fibroblasts by inhibiting mitochondrial
fission, which improves defective respiration, but does not rescue
mtDNA depletion, cristae dysmorphology, or apoptotic sensitivity.
Our data reveal that the multifaceted roles of OPA1 in mitochon-
dria can be functionally uncoupled by modulating mitochondrial
lipid metabolism, providing novel insights into the cellular rele-
vance of mitochondrial fragmentation.
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Introduction
The morphology that mitochondria adapt within a cell is shaped by
opposing events of membrane fusion and fission executed by
dynamin-like GTPases (Giacomello et al, 2020). Fission is performed
upon recruitment of dynamin-related protein 1 (DRP1, encoded by
DNM1L) to the outer membrane (OMM) via its receptors mitochon-
drial fission factor (MFF) and mitochondrial division (MiD) 49 and
51, which coalesce at sites of contact with the endoplasmic reticu-
lum (ER)(Friedman et al, 2011) in a manner that depends on the
lipid composition of the OMM (Choi et al, 2006; Khacho et al,
2014). Mitochondrial fusion is controlled by Mitofusins (MFN) 1
and 2 at the outer membrane and optic atrophy protein 1 (OPA1) in
the inner membrane (IMM) (Chen et al, 2003; Olichon et al, 2003;
Cipolat et al, 2004). Post-translational modifications (PTM) of these
proteins can regulate mitochondrial dynamics: DRP1 phosphoryla-
tion can alter the recruitment to future sites of mitochondrial divi-
sion on OMM while at the IMM, proteolytic cleavage of OPA1 from
L-OPA1 to S-OPA1 by the mitochondrial proteases OMA1 and the i-
AAA protease YME1L balances the rates of fusion and fission in
response to stress conditions and metabolic stimulation (MacVicar
& Langer, 2016).
Mitochondrial shape can shift in response to cellular and extra-
cellular cues both in vitro and in vivo (Twig et al, 2008; Gomes
et al, 2011; Arruda et al, 2014; Khacho et al, 2014; Jacobi et al,
2015). Mitochondrial fusion has been proposed to preserve cellular
integrity, increase ATP production, and maintain mitochondrial
DNA levels (mtDNA) (Chen et al, 2010; Elachouri et al, 2011).
Stress-induced mitochondrial hyperfusion (SiMH) is a cytoprotective
response that occurs in response to exogeneous cellular insults
including protein synthesis inhibition and nutrient and oxygen
deprivation (Tondera et al, 2009; Gomes et al, 2011; Rambold et al,
1 Mitochondrial Biology Group, Institut Pasteur, CNRS UMR 3691, Paris, France
2 Universite de Paris, Paris, France
3 Max-Planck-Institute for Biology of Ageing, Cologne, Germany
4 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
5 UTechS Ultrastructural Bio Imaging, Institut Pasteur, Paris, France
6 Cambridge Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
7 Cambridge Eye Unit, Addenbrooke’s Hospital, Cambridge University Hospitals, Cambridge, UK
8 Moorfields Eye Hospital, London, UK
9 UCL Institute of Ophthalmology, University College London, London, UK
10 Laboratoire de Biochimie et biologie moleculaire, Centre Hospitalier Universitaire, Angers, France
11 Unite Mixte de Recherche MITOVASC, CNRS 6015, INSERM U1083, Universite d’Angers, Angers, France
*Corresponding author. Tel: +33 1 44 38 91 41; E-mail: timothy.wai@pasteur.fr
ª2021 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine e13579 | 2021 1 of 29
2011; Khacho et al, 2014) characterized by an elongation of the
mitochondrial network resulting from unopposed fusion that
requires OPA1 and MFN1 (but not MFN2) and the IMM proteolytic
scaffold protein stomatin-like protein 2 (SLP2) (Tondera et al, 2009;
Wai et al, 2016). SLP2 is a cardiolipin (CL)-binding protein that
defines CL-rich membrane domains of the IMM. CL is a
mitochondrial-specific non-bilayer-forming phospholipid that is
implicated in a wide array of mitochondrial processes including
apoptosis, respiratory chain assembly, protein import, inflamma-
tion, and mitochondrial dynamics (Claypool, 2009). The association
between mitochondrial dynamics and lipids in mitochondrial and
cellular homeostasis is well established, although the nature of this
interdependence is less clear.
Unopposed fission causes mitochondrial fragmentation, which is
associated with cellular dysfunction and has been observed in a
variety of acquired and inborn disorders, in particular mitochondrial
genetic diseases (MD) (Giacomello et al, 2020). Mutations in OPA1,
which encodes for a dynamin-like GTPase protein, cause autosomal
dominant optic atrophy (DOA). The majority of patients manifest
isolated optic atrophy (DOA, MIM#165500), but a subgroup develop
a more severe disseminated neurological phenotype as part of a
DOA “plus” phenotype (DOA+, MIM#125250), including an early-
onset Behr-like syndrome (MIM#210000) or encephalomyopathy
(MIM# 616896) in a few reported patients with recessive OPA1
mutations (Carelli et al, 2015; Spiegel et al, 2016). OPA1-deficient
cells exhibit a fragmented mitochondrial network due to unopposed
fission (Olichon et al, 2003; Cipolat et al, 2004). Beyond mitochon-
drial fusion, OPA1 plays essential roles in the maintenance of cristae
shape, mtDNA levels, OXPHOS complex assembly, cellular prolifera-
tion, and apoptotic sensitivity (Giacomello et al, 2020). Over-
expression of OPA1 can confer protection against apoptotic cell
death (Varanita et al, 2015) without necessarily altering mitochon-
drial morphology (Frezza et al, 2006), leading to the notion that
non-fusion roles of OPA1 (e.g., cristae maintenance) are function-
ally separable from IMM fusion but this hypothesis has never been
put to the test in OPA1 deficiency (Patten et al, 2014). Indeed, how
OPA1 is capable of regulating different processes within mitochon-
dria is unclear as is the cellular relevance of mitochondrial fragmen-
tation in OPA1-deficient cells.
Mitochondrial morphology exists on a dynamic spectrum, with
fragmented and hypertubulated (or hyperfused) referring to the char-
acteristic network morphologies adopted by mitochondria in cells
when fusion and fission are inhibited, respectively (Giacomello
et al, 2020). Quantification of mitochondrial morphology performed
by subjective, user-defined manual classification cells with aberrant
mitochondrial networks caused by inhibited fusion (Ishihara et al,
2006) or fission (Osellame et al, 2016) as well as enhanced fusion
(Tondera et al, 2009; Wai et al, 2016) or fission (Anand et al, 2014)
has been successfully applied for the over two decades. More
recently, the use of computer-assisted segmentation measurement of
mitochondrial features (Kane et al, 2017), such as the length, width,
or aspect ratio of mitochondria has gained traction (Iannetti et al,
2016). However, major drawbacks to these approaches remain the
manual collection of images, the possibility of user bias, and the
laborious segmentation of mitochondria needed to ascribe morpho-
logical traits. The latter also requires spatial resolution at the physi-
cal limits of light microscopy in order to accurately and
unequivocally separate one mitochondrion from the next. While
recent advances in super-resolution nanoscopy of mitochondria may
soon render this concern moot (Jakobs et al, 2020), only a handful
of laboratories have successfully applied this technology for high-
resolution mitochondrial imaging and its application to high-
throughput imaging has yet to be established.
In this study, we developed a first-in-kind, high-throughput
imaging screening pipeline and identified known and novel mito-
chondrial genes that can modulate mitochondrial morphology in
healthy human fibroblasts and prevent mitochondrial fragmentation
in OPA1 patient fibroblasts, most of which have never previously
been linked to mitochondrial dynamics. Among the 91 candidate
genes found to suppress mitochondrial fragmentation, we discov-
ered that depletion of PGS1, the mitochondrial phosphatidyl glyc-
erophosphate (PGP) synthase, lowers cardiolipin levels, inhibits
mitochondrial fission and rescues mitochondrial fragmentation and
respiration in OPA1-deficient mouse embryonic fibroblasts. Our data
unravel an unexpected role of PGS1 in the regulation of mitochon-
drial form and function.
Results
Inhibiting fission rescues mitochondrial fragmentation in OPA1
patient fibroblasts
To overcome limitations of conventional approaches for imaging
and quantification of mitochondria in cells, we developed a high-
content imaging pipeline using confocal spinning disk fluorescence
microscopy compatible with multi-well, high-throughput automated
imaging of live or fixed cells (Fig EV1). We adopted an image analy-
sis pipeline (Dataset EV1) that automatically executes cell segmenta-
tion enabling the single-cell classification of mitochondrial
morphology using supervised machine learning (ML) algorithms
trained on defined classes of mitochondrial morphologies, which do
not rely on measuring the absolute length or width of a mitochon-
drion. Instead, training sets (ground truths) were empirically gener-
ated by knocking down genes whose depletion is known to provoke
either increased or decreased mitochondrial network lengths. To
promote mitochondrial fragmentation, we depleted control fibrob-
lasts of OPA1, and to define hypertubulated mitochondria, we inhib-
ited mitochondrial fission by downregulation of DNM1L. To define
normal, tubular mitochondrial morphology, we treated control cells
with non-targeting (NT) siRNAs. Confocal images of hundreds of
cells (315–586 cells/training condition) acquired from these training
sets were used as ground truths to train the supervised ML algo-
rithm to classify cells as either fragmented, normal, or hypertubu-
lated (Fig 1A) during each imaging experiment. This approach
proved tremendously robust: siRNA-mediated induction of fragmen-
tation of either YME1L or MFN1/2 was accurately recognized as
such by supervised ML training of mitochondrial fragmentation
using OPA1 siRNAs (Appendix Fig S1A) and chemical induction of
fission with the protonophore carbonyl cyanide m-chlorophenyl
hydrazone (CCCP) or hyperfusion with the cytosolic protein synthe-
sis inhibitor cycloheximide (CHX) could be used to accurately quan-
tify mitochondrial fragmentation in OPA1-depleted fibroblasts
(Appendix Fig S1B). Together, these data validate the supervised
ML approach to mitochondrial morphology quantification as a
rapid, robust, and unbiased approach for the quantitative
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assessment of mitochondrial shape in fibroblasts using a variety of
genetic or chemical training sets as ground truths.
Genetic knockouts, siRNA depletion, and chemical modulation
experiments induce drastic alterations in mitochondrial shape that
are easily recognizable but do not necessarily reflect the phenotypic
severity observed in patient cells or disease models, which are often
hypomorphic, yielding more subtle biochemical and cell biological
alterations. To determine whether our supervised ML approach to
mitochondrial morphology quantification was compatible with the
high-throughput interrogation of patient cells, we imaged and
analyzed control and DOA+ patient-derived skin fibroblasts carrying
pathogenic, mono-allelic variants in OPA1 known to cause mito-
chondrial fragmentation including p.Arg445His (OPA1R445H) and
p.Ser545Arg (OPA1S545R) (Amati-Bonneau et al, 2005; Yu-Wai-Man
et al, 2010) and pathogenic variants whose effects on mitochondrial
morphology have not yet been reported such as p.Ile432Val
(OPA1I432V), c.2356G>T (OPA1c.2356G>T), and p.Gln297*(OPA1Q297X)
(Yu-Wai-Man et al, 2010) (Fig 1B and Table 1). Our analyses
revealed both OPA1S545R and, to a lesser extent, OPA1R445H patient
fibroblasts exhibited significant increases in the proportion of cells
with a fragmented mitochondrial phenotype: 45.2  5.3% of
OPA1S545R fibroblasts (2,282 cells analyzed) and 16.8  9.2% of
OPA1R445H fibroblasts (2,683 cells analyzed) were fragmented
compared with 4.5–11.1% of control fibroblasts from three healthy,
unrelated individuals (CTL-1; 11.1  7.1%, CTL-2; 6.1  3.2%,
CTL-3; 4.5  5.2%, 879–3,823 cells analyzed; Fig 1B and C). These
data are in accordance with previous measurements made in these
cells using manual, lower-throughput imaging and quantification
methods (Amati-Bonneau et al, 2005; Kane et al, 2017). Curiously,
we did not detect significant mitochondrial morphology defects in
OPA1I432V, OPA1c.2356-1G>T nor OPA1Q297X patient fibroblasts even
though they were derived from patients also suffering from the same
pathology: DOA+. Western blot analyses revealed a reduction in
OPA1 protein of 58.2%  9.2 in OPA1Q297X lysates (Appendix Fig
S1C) relative to control fibroblasts and no significant differences in
other patient-derived fibroblasts. Aberrant mitochondrial morphol-
ogy measured in patient-derived fibroblasts did not correlate with
the steady-state levels of OPA1 nor with the reported clinical symp-
toms (Table 1), suggesting that additional factors beyond patho-
genic mutations in OPA1 may be capable of modulating
mitochondrial morphology.
In animal models of MD, mitochondrial fragmentation can be rebal-
anced by additional inhibition of mitochondrial fission (Wai et al,
2015; Yamada et al, 2018), but this approach has not been tested in
humans. To test whether decreasing mitochondrial fission is capable
of rebalancing mitochondrial morphology in OPA1 mutant patient
fibroblasts, we knocked down DNM1L by siRNA (Fig 1D). DRP1 deple-
tion in OPA1S545R fibroblasts led to an increased proportion of cells
with normal and hypertubular mitochondria while reducing those with
fragmented mitochondria (Fig 1E), reaching proportions similar to
those observed in control fibroblasts (13.4%  11.0 in CTL-1 vs.
18.5%  13.9 in OPA1S545R). These data indicate that inhibiting fission
can restore mitochondrial morphology in OPA1 mutant fibroblasts
exhibiting mitochondrial fragmentation. In addition, depletion of
OPA1 by siRNA treatment in OPA1S545R patient fibroblasts further
increased mitochondrial fragmentation by 34.5% (1.34-fold change),
implying partial functionality of OPA1 protein present in OPA1S545R
patient fibroblasts. Indeed, treatment of OPA1S545R patient fibroblasts
with CHX led to an elongation of the mitochondrial network (Fig 1F)
characterized by reduced mitochondrial fragmentation (Fig 1G), indi-
cating that OPA1S545R cells are capable of performing SiMH and there-
fore retain some functional OPA1 (Tondera et al, 2009). These data
lend experimental support to a previously proposed genetic haploin-
sufficiency in DOA (Pesch et al, 2001) caused by mono-allelic patho-
genic variants. Taken together, these data outline a straightforward
and unbiased manner to identify and correct mitochondrial fragmenta-
tion in patient-derived fibroblasts.
High-throughput screening identifies known and novel modifiers
of mitochondrial morphology in control fibroblasts
In an effort to identify mitochondrial proteins that regulate OPA1
dynamics, we established an imaging-based screening pipeline to
quantitatively assess the impact of all mitochondrial genes on mito-
chondrial morphology. To do this, we coupled automated imaging
and supervised ML mitochondrial morphology quantification work-
flow (Fig 1A) with a bespoke siRNA library targeting 1,531 known
and putative nuclear-encoded mitochondrial genes (henceforth
termed the Mitome siRNA library) generated based on publicly
accessible databases of mitochondrial genes (Smith & Robinson,
2019; Rath et al, 2021) (see Dataset EV2 for gene list and plate distri-
bution). This list is more extensive than MitoCarta 3.0 and also
◀ Figure 1. Inhibition of mitochondrial division prevents mitochondrial fragmentation caused by OPA1 deficiency in DOA+ patient-derived fibroblasts.
A Schematic of supervised machine learning (ML) mitochondrial morphology imaging and quantification pipeline. Fibroblasts plated in 384-well plates are stained for
mitochondria (anti-TOMM40, green), nuclei (DAPI, blue), and cell body (CellMask, blue). Supervised ML training performed on cells with fragmented (OPA1 or YME1L
siRNA), normal (non-targeting NT siRNA), and hypertubular (DNM1L siRNA) mitochondria. Automatic single-cell trinary classification of control (CTL-1, 2, 3) and
OPA1S545R patient fibroblasts by supervised ML.
B Representative confocal images of control (CTL-1, 2, 3) and DOA+ patient fibroblasts carrying indicated mono-allelic mutations imaged as described in (A). Scale
bar = 20 μm. Passage number between P12–15.
C Mitochondrial morphology quantification of (B). Data represent mean  SD of two independent experiments, (195–2,496 cells per cell line), One-way ANOVA;
**P < 0.01, ****P < 0.0001, ns; not significant.
D Representative confocal images of control (CTL-1) and OPA1S545R patient fibroblasts treated with OPA1, DNM1L, or non-targeting (NT) siRNAs for 72 h and imaged as
described in (A). Scale bar = 20 μm. Passage number between P12–14.
E Mitochondrial morphology quantification of (D). Data represent mean  SD of three independent experiments (3,219–5,857 cells per cell line), One-way ANOVA;
****P < 0.0001, ns; not significant.
F Representative confocal images of control (CTL-1) and OPA1S545R patient fibroblasts treated with 50 μM cycloheximide (CHX) where indicated for 6 h. Imaging as
described in (A). Scale bar = 20 μm. Passage number between P14–P15.
G Mitochondrial morphology quantification of (F). Data represent mean  SD of two independent experiments (879–4,154 cells per cell line), One-way ANOVA;
****P < 0.0001, ns; not significant.
Source data are available online for this figure.
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includes targets gene products whose function and localization have
not yet been experimentally defined. SmartPool siRNAs (4 siRNAs
per gene per pool) were spotted individually across six 384-well
plates, which also contained siRNAs for DNM1L, OPA1, and YME1L
that could serve as read-outs for downregulation efficiency within
and between plates as well as ground truths for supervised ML
(Fig EV2A–C, (Z-score = 0.72875  0.1106). We began by Mitome
screening in healthy control fibroblasts (CTL-1 and CTL-2) and iden-
tified 22 genes whose downregulation led to the fragmentation of
the mitochondrial network and 145 genes that lead to hypertubula-
tion above thresholds that were defined post hoc using a univariate
3-component statistical model we developed in R (Dataset EV3).
Among the genes whose ablation induced mitochondrial fragmenta-
tion, we identified established components required for the mainte-
nance of tubular mitochondria including YME1L, OPA1, and MFN1
(Fig 2B, Dataset EV3). We also identified factors already described
to modify mitochondrial morphology including AMBRA1, GOLPH3,
and PPTC7. AMBRA1, which stands for activating molecule in
Beclin-1-regulated autophagy, is an autophagy adapter protein regu-
lated by mTORC1 that has been linked to mitophagy and
programmed cell death, all of which are associated with fragmenta-
tion of the mitochondrial network. Golgi phosphoprotein 3
(GOLPH3) regulates Golgi morphology and mitochondrial mass and
cardiolipin content through undefined mechanisms (Sechi et al,
2015). PPTC7 encodes a mitochondrial phosphatase shown to be
essential for post-natal viability in mice. EM analyses in heart and
liver sections of Pptc7−/− mice revealed smaller, fragmented mito-
chondria (Niemi et al, 2019), consistent with our findings in human
fibroblasts (Appendix Fig S2A).
Among the genes whose ablation induced mitochondrial hyper-
tubulation (Fig 2C), we identified DNM1L, its receptors MIEF1 and
MFF, as well as USP30 and SLC25A46. USP30 encodes a deubiquiti-
nase that is anchored to the OMM where it contributes to mitochon-
drial fission in a DRP1-dependent fashion (Bingol et al, 2014).
Depletion of USP30 has been shown to promote mitochondrial elonga-
tion and mitophagy (Nakamura & Hirose, 2008). SLC25A46, which
encodes for an outer membrane protein with sequence homology to
the yeast mitochondrial dynamics regulator Ugo1, is required for
mitochondrial fission. In human fibroblasts, depletion by siRNA or
pathogenic loss-of-function variants leads to hypertubulation of the
mitochondrial network (Abrams et al, 2015; Janer et al, 2016). Simi-
larly, depletion of MFF and/or MiD51 in fibroblasts inhibits DRP1-
dependent mitochondrial fission and results in mitochondrial hyper-
tubulation (Osellame et al, 2016). Pathogenic variants in MFF cause
optic and peripheral neuropathy and fibroblasts from these patients
exhibit mitochondrial elongation (Koch et al, 2016). In addition to
known regulators of mitochondria morphology, we also discovered a
number of known mitochondrial genes whose functions have not
previously associated with mitochondrial dynamics, including LIPT1,
LIPT2, and BCKDHA. LIPT1 and LIPT2 encode mitochondrial lipoyl-
transferases, which are involved in the activation of TCA cycle
enzyme complexes and branched-chain ketoacid dehydrogenase
(BCKD) complex. BCKDHA the E1-alpha subunit of the BCKD that is
involved in the catabolism of amino acids isoleucine, leucine, and
valine. Mutations in either LIPT1 (Soreze et al, 2013, 1), LIPT2
(Habarou et al, 2017, 2), or BCKDHA (Flaschker et al, 2007) causes
inborn errors of metabolism, although the effects on mitochondrial
morphology have never been investigated. Finally, we also discovered
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a cluster of genes (Appendix Fig S2B) encoding proteins required for
ribosome assembly and cytosolic translation (RPL10, RPL10A, RPL8,
RPL36AL, RPS18). To our knowledge, depletion of cytosolic ribosomal
genes has never been associated with mitochondrial hyperfusion,
although chemical inhibition of proteins synthesis is the most
commonly used trigger for SiMH (Tondera, 2005). These data are
consistent with the mitochondrial elongation induced by treatment of
control fibroblasts (Fig 1G and H) with CHX, which inhibits cytosolic
translation. Altogether, our data demonstrate the robustness of our
imaging-based phenotypic screening and mitochondrial morphology
quantification approach for the identification of both known and
novel genes controlling mitochondrial morphology and provide a
valuable resource for the investigation of mitochondrial dynamics.
High-throughput screening in patient-derived OPA1 mutant
fibroblasts identifies suppressors of mitochondrial fragmentation
We sought to apply the Mitome screening approach to identify
novel regulators of OPA1 acting as genetic suppressors of mito-
chondrial fragmentation in OPA1S545R fibroblasts. After 72 h of
siRNA treatment, we acquired images of hundreds of cells per well
(257–1,606) and then classified mitochondrial morphology by
applying a training sets comprised of OPA1S545R fibroblasts trans-
fected with NT siRNAs (fragmented), OPA1 siRNAs (hyperfrag-
mented), or DNM1L siRNAs (rescued). Application of our imaging
and quantification pipeline identified 91 candidate genes whose
downregulation rescued mitochondrial fragmentation (Figs 2D and
EV2C, Dataset EV4) as well as 27 genes that further fragmented the
mitochondrial network (Fig EV2D and E, Dataset EV4) such as
OPA1, YME1L, and SURF1. As expected, among the 91 candidates,
39 of these genes were also discovered to hypertubulate mitochon-
dria in control fibroblasts upon downregulation (Fig 2C and F),
including regulators of mitochondrial fission such as SLC25A46
(Janer et al, 2016), MFF (Gandre-Babbe & van der Bliek, 2008),
MIEF1 (Osellame et al, 2016, 49), and DNM1L (Smirnova et al,
2001). We also discovered factors interacting with the MICOS
complex (DNAJC4, DNAJC11), which was unexpected given that
disruption of the MICOS and respiratory chain complexes is usually
associated with fragmentation rather than elongation of the mito-
chondrial network (Stephan et al, 2020). Nevertheless, validation
studies revealed that depletion of DNAJC4 or 11 could rescue mito-
chondrial fragmentation caused by OPA1 deficiency (Fig EV2F and
G). Like in control fibroblasts, our data revealed a cluster of riboso-
mal genes bioinformatically predicted to be targeted to mitochon-
dria according to the Integrated Mitochondrial Protein Index
(IMPI) score of the Mitominer 4.0 database including RPL15,
RPS15A, RPLP2, RPL36AL, RPL5, and RPS18, essential for cytosolic
translation, implying that inhibition of protein synthesis can
suppress mitochondrial fragmentation in OPA1S545R patient fibrob-
lasts. These data are concordant with the discovery that OPA1S545R
patient fibroblasts can perform SiMH in the presence of the cytoso-
lic protein inhibitor CHX (Fig 1F and G). The Mitome siRNA screen
of OPA1S545R fibroblasts identified a wide array of well-
characterized genes not previously linked to mitochondrial dynam-
ics including some required for mitochondrial gene expression and
maintenance (TFB1M, MTERF4, MRPL53, GFM2, MRPS18A), oxida-
tive phosphorylation (NDUFAF1, COX6A2, ETHE1, COX20,
ETFDH), amino acid metabolism (BCKDHA, GLUD2, DAOA,
MCCC1, GLYAT), one-carbon and serine metabolism (MMAA,
SHMT2, MTHFD1L, MTHFD2L), and lipid biosynthesis (PGS1,
PISD, BZRAP1) as well as orphan genes (C15orf62, C15orf61,
C3orf33; Fig 2E, Dataset EV4). In conclusion, we successfully
applied an unbiased, high-throughput imaging approach and iden-
tified a large number of candidate suppressors of mitochondrial
dysfunction in MD patient-derived fibroblasts, none of which are
known to be implicated in the modulation of clinical or biochemi-
cal severity caused by OPA1 mutations.
PGS1 depletion rescues mitochondrial fragmentation in OPA1-
deficient fibroblasts
One of the top hits from the Mitome siRNA screen able to rescue
aberrant mitochondrial morphology in OPA1S545R patient fibroblasts
or promote mitochondrial hypertubulation in control fibroblasts,
▸Figure 2. High-throughput screening identifies known and novel genetic modifiers of mitochondrial morphology in control and DOA+ patient-derivedfibroblasts.
A Schematic of Mitome siRNA imaging screen for mitochondrial morphology in control human fibroblasts. Fibroblasts were reverse-transfected with siRNAs directed
against 1,531 nuclear-encoded mitochondrial genes in 384-well plates and stained for mitochondria (anti-TOMM40, green), nuclei (DAPI, blue), and cytoplasm
(CellMask, blue). Supervised ML training performed on control fibroblasts treated with siRNAs for OPA1 or YME1L (fragmented) NT control (normal), and DNM1L
(hypertubular) were applied to single-cell trinary classification of Mitome siRNA-treated fibroblasts. Passage number P14.
B Candidate siRNAs (purple) causing mitochondrial fragmentation relative to grounds truths for fragmentation (OPA1 siRNA). Violin plot representing % fragmented
morphology of Mitome siRNAs (purple). Hits were selected with a univariate three-components statistical model programmed in R using ground truths (n = 30) for
morphology shown in (A). The defined threshold for positive hits (thick dotted line inset) was 68.9% (solid dash on the y-axis and thin dotted line in the inset) and
identified 22 candidate genes, including OPA1, YME1L, and AMBRA1 from two independent experiments.
C Candidate siRNAs (purple) causing mitochondrial hypertubulation relative to grounds truths for hypertubulation (DNM1L siRNA). Violin plot representing %
hypertubulated morphology of Mitome siRNAs (purple). Hits were selected with a univariate 3-components statistical model programmed in R using ground truths
(n = 30) for morphology shown in (A). The defined threshold for positive hits (thick dotted line inset) was 69.2% (solid dash on the y-axis and thin dotted line in the
inset) and identified 145 candidate genes, including DNM1L, MIEF1, and PGS1 from two independent experiments.
D Schematic of Mitome siRNA imaging screen in OPA1S545R patient fibroblasts. Fibroblasts transfection and imaging as described in A. Supervised ML training performed
on OPA1S545R fibroblasts treated with siRNA for OPA1 (hyperfragmented) NT control (normal), and DNM1L (rescued) were applied to single-cell trinary classification of
OPA1S545R patient fibroblasts. Passages number P12.
E Violin plot representing % rescued morphology of Mitome siRNAs. The siRNA able to rescue mitochondrial fragmentation were selected with a univariate 3-
components statistical model programmed in R using the following ground truths for morphology: fragmented (NT siRNA, n = 30), rescued (DNM1L siRNA, n = 30),
and hyperfragmented (OPA1 siRNA, n = 30). The defined threshold for positive rescued hits (thick dotted line inset) was 49.81% (solid dash on the y-axis and thin
dotted line in the inset) and identified 91 candidate genes from one experiment.
F Overlap between 91 candidates identified in (E) and (C) identify 38 overlapping genes leading to mitochondrial elongation (hypertubulation in CTL-1, CTL-2, and
rescued in OPA1S545R fibroblasts) and 53 genes that specifically rescue mitochondrial fragmentation in OPA1S545R fibroblasts.
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PGS1, encodes a CDP-diacylglycerol-glycerol-3-phosphate 3-
phosphatidyltransferase (Chang et al, 1998) that catalyzes the
synthesis of phosphatidylglycerol phosphate (PGP), the rate-limiting
step in the synthesis of cardiolipin (CL; Fig 5A) (Tamura et al,
2020). CL is a mitochondria-specific phospholipid synthesized and
primarily located in the IMM and is important for various mitochon-
drial functions including protein and metabolite import, cristae
maintenance, programmed cell death regulation, and oxidative
phosphorylation (Dudek, 2017). Recent work from the Ishihara
laboratory reported CL to be important for membrane fusion by
OPA1, implying that CL deficiency would impair mitochondrial
fusion and drive fragmentation (Ban et al, 2017).
We sought to confirm that PGS1 depletion indeed inhibits mito-
chondrial fragmentation by treating OPA1S545R fibroblasts with
siRNAs directed against it. PGS1 depletion significantly reduced the
proportion of cells with fragmented mitochondria, and we discov-
ered it could only do so if OPA1 was not totally depleted (Fig 3A
and B). OPA1S545R patient fibroblasts and OPA1 siRNA-treated CTL-
1 fibroblasts were resistant to mitochondrial elongation by PGS1
depletion, although DNM1L ablation could still rescue mitochondrial
fragmentation in these cells. These data argue that PGS1 depletion is
effective in rebalancing mitochondrial dynamics in the context of a
hypomorphic OPA1 mutations (Del Dotto et al, 2018) and not when
OPA1 is completely absent.
Functional exploration of mitochondrial biology in primary
human fibroblasts is challenging due to the slow proliferation rates,
low metabolic activity, poor transfection efficiency, genetic hetero-
geneity, and cellular senescence. To circumvent these limitations,
we pursued further studies in mouse embryonic fibroblasts (MEFs)
in which we partially (Opa1Crispr) or completely (Opa1KO) ablated
OPA1 (Fig EV3A and B). To generate hypomorphic Opa1 mutant
MEFs (Opa1Crispr), we employed Crispr/Cas9 to initiate a targeted
disruption of Exon 4, which is in the most highly expressed func-
tional splice isoforms of the eight isoforms of Opa1 in mice (Song
et al, 2007; Akepati et al, 2008) (Fig EV3A). We sorted individual
Opa1Crispr MEF clones by flow cytometry and screened for positive
clones using mitochondrial fragmentation as an initial readout. DNA
sequencing of Opa1 in positive clones was performed by Illumina
HighSeq Deep Sequencing of PCR amplicons covering the targeted
region. Opa1Crispr MEFs harbored a c.5013delA mutation, predicted
to prematurely truncate OPA1 at position 178, and a 107 bp deletion
at c.503 extending through the end of Exon 4 and into Intron 4,
predicted to prematurely truncate OPA1 at position 182 in Exon 5.
These deletions yielded frameshift and missense mutations causing
a ~ 80% reduction in steady-state protein levels in Opa1Crispr MEFs
(Fig 3G and H) and a ~ 50% reduction in Opa1 mRNA levels (Fig
EV3C), which could also be effectively achieved by siRNA-mediated
downregulation (Fig EV3D). Opa1Crispr MEFs exhibited mitochon-
drial fragmentation (Fig 3C and D) that could be rescued by stable
re-expression of OPA1 isoform 1 with (Fig EV3D–F) or without a C-
terminal 9xMyc tag construct (Mishra et al, 2014) (Fig 3E and F),
validating the targeted disruption of Opa1. Similarly to hypomorphic
OPA1S545R patient-derived fibroblasts, Opa1Crispr MEFs exhibited
hypomorphy, as evidenced by the ability of Opa1 siRNA treatment
to further increase mitochondrial fragmentation (Appendix Fig S4A
and B) to levels observed in Opa1KO MEFs (Appendix Fig S4E and
F) and the ability of Opa1Crispr MEFs to undergo SiMH
(Appendix Fig S4C and D), which was not possible in Opa1KO MEFs
(Appendix Fig S4E and F).
Next, we tested whether PGS1 depletion could rescue mitochon-
drial fragmentation in Opa1Crispr MEFs. PGS1 ablation, either by
siRNA (Fig 3C and D) or Crispr/Cas9-mediated NHEJ (Fig 3E and F)
prevented mitochondrial fragmentation, leading to the re-
establishment of wild-type mitochondrial network morphology.
qRT–PCR measurement of Pgs1 mRNA levels showed a 25  8.3%
reduction in Pgs1 mRNA in Opa1CrisprPgs1Crispr MEFs (Fig EV3C)
and a 71.9  8.4% percent reduction in Pgs1 siRNA-treated
Opa1Crispr MEFs (Fig 5D). To confirm that mitochondrial morphol-
ogy rescue in Opa1CrisprPgs1Crispr MEFs did not arise from unlikely
and unintended reversions of mutant Opa1, we performed DNA
sequence analyses by Illumina HighSeq Deep Sequencing of
Opa1CrisprPgs1Crispr MEF PCR amplicons from the targeted locus.
Opa1CrisprPgs1Crispr MEFs carried the same Opa1 loss-of-function
mutations as the parental Opa1Crispr MEFs as well as an additional
mutation in Pgs1 (c.218delGTGTA), predicted to result in a frame-
shift at Gly73. Stable re-expression of PGS1 restored Pgs1 mRNA
levels in Pgs1Crispr MEFs (Fig EV3C) and resulted in fragmentation
of the (rescued) mitochondrial network in Opa1CrisprPgs1Crispr MEFs
◀ Figure 3. PGS1 depletion rescues mitochondrial fragmentation in OPA1-deficient human and mouse fibroblasts.
A Representative confocal images of control (CTL-1) and OPA1S545R patient fibroblasts treated with OPA1, DNM1L, PGS1, and non-targeting (NT) siRNAs or indicated
combinations for 72 h. Mitochondria (anti-TOMM40, green) and nuclei (DAPI, blue). Scale bar = 20 μm. Passages number between P10–15.
B Mitochondrial morphology quantification of (A) using control fibroblasts with fragmented (OPA1 siRNA), normal (non-targeting NT siRNA), and hypertubulated
(DNM1L siRNA) mitochondria. Data represent mean  SD of three independent experiments, One-way ANOVA (905–3,695 cells per cell line), (% fragmented);
****P < 0.0001, ns; not significant.
C Representative confocal images of wild-type (WT) and Opa1Crispr MEFs treated with NT or Pgs1 siRNA for 72 h. Live imaging of mitochondria (mitoYFP, green) and
nuclei (NucBlue, blue). Scale bar = 10 μm.
D Mitochondrial morphology quantification of (C) using WT MEFs treated with Opa1 siRNA (fragmented), NT siRNA (normal), or Dnm1l siRNA (hypertubulated)
ground truth training sets. Data represent mean  SD of three independent experiments, One-way ANOVA (6,613–8,758 cells per cell line), (% fragmented);
****P < 0.0001, ns; not significant.
E Representative confocal images of WT, Opa1Crispr MEFs complemented with pLenti-Opa1, Opa1CrisprPgs1Crispr MEFs, and Pgs1Crispr MEFs complemented with pLenti-
Pgs1 by lentiviral delivery. Live imaging of mitochondria (mitoYFP, green) and nuclei (NucBlue, blue). Scale bar = 10 μm.
F Supervised ML mitochondrial morphology quantification of (E) using WT MEFs treated with Opa1 siRNA (fragmented), NT siRNA (normal), or Dnm1l siRNA
(hypertubulated) training sets. Data represent mean  SD of three independent experiments, One-way ANOVA (691–3,990 cells per cell line), (% fragmented);
****P < 0.0001, ns; not significant.
G, H (G) Equal amounts of protein extracted from MEFs were separated by SDS–PAGE, immunoblotted with anti-OPA1 antibody, and quantified (H) by densitometry
relative to Stain-Free. Data represent mean  SD of three independent experiments, One-way ANOVA; *P < 0.05, ***P < 0.001, ****P < 0.0001, ns; not significant.
Source data are available online for this figure.
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(Fig 3E and F) back to WT levels. To exclude the possibility that
PGS1 depletion rescues mitochondrial morphology of Opa1Crisprr
MEFs by indirectly elevating OPA1 expression, we assessed OPA1
protein levels by Western blot. Opa1CrisprPgs1Crispr MEFs exhibited
levels of total OPA1 levels and L-OPA1/S-OPA1 ratios (Fig 3G and
H) similar to the parental Opa1Crispr cells, indicating that restored
mitochondrial morphology in Opa1CrisprPgs1Crispr MEFs is not the
result of rescued OPA1 expression. Taken together, our results
demonstrate that PGS1 depletion can rescue mitochondrial fragmen-
tation caused by OPA1 deficiency in both mouse and human fibrob-
lasts.
PGS1 depletion rescues mitochondrial fragmentation by
inhibiting mitochondrial fission
We sought to understand whether PGS1 depletion restores normal
mitochondrial morphology by increasing mitochondrial fusion or
reducing mitochondrial fission. We examined the levels of proteins
involved in mitochondrial dynamics by Western blot (Fig EV4A and
B), and we observed no significant alterations in the steady-state
levels of known fusion (MFN1, MFN2) and fission (MFF, MiD49,
MiD51, FIS1) regulators in Opa1CrisprPgs1Crispr MEFs, yet we did
observe elevated DRP1 levels in Opa1Crispr MEFs, which returned to
WT levels in Opa1CrisprPgs1Crispr MEFs. To test whether increased
levels of DRP1 promoted its recruitment to mitochondria, we stably
expressed mitoTag constructs (3XHA-EGFP-OMP25 or 3XMyc-EGFP-
OMP25) in MEFs in order to perform affinity purification and parti-
tioning of mitochondria from cytosolic contents (Chen et al, 2016).
Immunoblot analyses demonstrated an increase in total DRP1 levels
in Opa1Crispr mitoTag MEFs compared with other genotypes but did
not show an increase in the partitioning of mitochondrial and non-
mitochondrial (cytosolic) DRP1 at steady state (Fig 4A). We further
corroborated these findings by examining the subcellular distribu-
tion of DRP1 by indirect immunochemistry studies, which also
revealed no differences in DRP1 colocalization Opa1Crispr,
Opa1CrisprPgs1Crispr, and Pgs1Crispr MEFs relative to WT (Fig 4B).
MEFs deleted of all three essential DRP1 receptors, Mid51/Mid49/
Mff, exhibited markedly less DRP1 recruitment as previously
demonstrated and were used as a negative control (Osellame et al,
2016). Live confocal imaging of endogenously, fluorescently tagged
DRP1 in WT and Opa1Crispr MEF (WTDrp1KI and Opa1Crispr-Drp1KI
MEFs, respectively) showed no differences in the degree of subcellu-
lar distribution of DRP1 in the presence or absence of PGS1 (Fig
EV4D and E). We also assessed the phosphorylation status of DRP1
by immunoblot analysis using site-specific antibodies for mouse
serine 579 (S579, which is equivalent to S600 for human DRP1) and
mouse serine 600 (S600, which is equivalent to S637 for human
DRP1; Appendix Fig S5A and B). Opa1Crispr MEFs showed increased
S579 phosphorylation of DRP1, consistent with the pro-fission role
of this post-translational modification, which was lowered to wild-
type levels in Opa1CrisprPgs1Crispr MEFs. Consistent with these obser-
vations, DRP1 oligomerization assessed by chemical cross-linking
(Karbowski et al, 2007; Prudent et al, 2015) did not reveal
genotype-specific differences (Appendix Fig S5C). Altogether, these
data indicate the altered DRP1 recruitment to mitochondria does not
explain the restoration of mitochondrial morphology caused by the
depletion of PGS1 in Opa1Crispr MEFs.
To assess mitochondrial division in living Opa1CrisprPgs1Crispr
MEFs, we performed quantitative kinetic measurements of mito-
chondrial morphology in the presence of established pharmacologi-
cal inducers of mitochondrial fragmentation: CCCP and the Ca2+
ionophore 4Br-A23187. Both chemicals cause DRP1-dependent mito-
chondrial fragmentation but CCCP triggers OMA1-dependent OPA1
processing (MacVicar & Langer, 2016) that both accelerates fission
and inhibits fusion while 4Br-A23187 treatment induces Ca2+-
dependent fragmentation without stress-induced OPA1 processing
(Adachi et al, 2016) (Fig EV4C). Treatment of Opa1CrisprPgs1Crispr
MEFs with CCCP (Fig 4C) or 4Br-A23187 (Appendix Fig S6A and B)
induced a progressive fragmentation of the mitochondrial network
over several hours with kinetics similar to that of WT MEFs, imply-
ing that rescued mitochondrial morphology conferred to Opa1Crispr
MEFs depleted (Fig 3C) or deleted (Fig 3E) was not caused by an
inhibition of DRP1. We discovered PGS1-depleted MEFs to be
largely resistant to CCCP-induced fragmentation for the duration of
the experiment: incubation with 5 μM CCCP for 10 h led to a 1.70
rate of fragmentation in WT MEFs and only 0.06 rate of
◀ Figure 4. PGS1 depletion rescues mitochondrial fragmentation by inhibiting mitochondrial fission.
A Equal amounts of protein extracted from total (T), cytosolic flow-through (C), and mitochondrial eluate (M) from MEFs of the indicated genotypes stably expressing
MitoTag (pMXs-3XHA-EGFP-OMP25) obtained following mitochondrial immunocapture were separated by SDS–PAGE, immunoblotted with indicated antibody, and
quantified by densitometry. Data represent mean  SD of three independent experiments, One-way ANOVA.
B Representative confocal images of MEFs of the indicated genotypes showing subcellular DRP1 distribution. Mitochondria (TOMM40, green), DRP1 labeled with anti-
DRP1 antibody (red) and nuclei (NucBlue, blue). Scale bar = 10 μm. MiD49/51/Mff KO MEFs lack all 3 DRP1 receptors (MiD49, MiD51, and MFF). Bar graph
representation of DRP1 localized to mitochondria (green) vs cytosol (blue). Data represent mean  SD of three independent experiments (884–3,116 cells per cell
line), unpaired t-test; *P < 0.05.
C Representative confocal images of live cell imaging of MEFs of the indicated genotypes subjected fragmentation with 5 μM carbonyl cyanide m-chlorophenyl
hydrazine (CCCP) for the indicated time points. Images were captured every hour for 18 h. Scale bar = 10 μm.
D Supervised ML mitochondrial morphology quantification using WT MEFs treated with 5 μM CCCP for 18 h (fragmented), untreated (normal), or treated with 10 μM
CHX for 9 h (hypertubular) training sets. Data represent mean  SD of three independent experiments (131–426 cells per cell line), One-way ANOVA; *P < 0.05,
**P < 0.01, ****P < 0.0001, ns; not significant.
E FRAP fusion assay in MEFs of the indicated genotype (see Movies EV1–EV3). Scale bar = 10 μm. Quantification of mitoYFP signal intensity measured at 200 ms
intervals in the photobleached area (green box) for the indicated time (seconds), represented as relative fold recovery post-bleach. Data represent mean  SEM of
two independent experiments (n = 18–52 cells per genotype), One-way ANOVA.
F Representative confocal images of live cell imaging of MEFs of the indicated genotypes subjected hyperfusion (SiMH) with 10 μM cycloheximide (CHX) for the
indicated time points. Images were captured every hour for 9 h.
G Mitochondrial morphology quantification of using WT MEFs treated with 5 μM CCCP for 18 h (fragmented), untreated (normal), or treated with 10 μM CHX for 9 h
(hypertubular) training sets. Data represent mean  SD of four independent experiments, (155–745 cells per cell line), One-way ANOVA.
Source data are available online for this figure.
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fragmentation in Pgs1Crispr MEFs (Fig 4C and D). Similarly, induc-
tion of mitochondrial fission with 4Br-A23187 did not promote mito-
chondrial fragmentation rates observed in WT MEFs (Appendix Fig
S6A and B). Given the resistance to uncoupler-induced mitochon-
drial fragmentation, we determined the mitochondrial membrane
potential of Pgs1Crispr MEFs by labeling MEFs with the potentiomet-
ric membrane marker TMRE, which we normalized to genetically
encoded mitoYFP. We observed a significant increase in membrane
potential in Pgs1Crispr MEFs (Appendix Fig S6C), which was reduced
upon stable re-expression of Pgs1, which also re-sensitized cells to
CCCP (Fig 4C and D) and 4Br-A23187-induced fragmentation
(Appendix Fig S6A and B). Despite the increase in basal membrane
potential, we observed no difference in the proclivity of Pgs1Crispr
MEFs to undergo proteolytic cleavage of OPA1 in response to CCCP-
induced OMA1 activation (Appendix Fig S6D), indicating that the
proteolytic activity of OMA1 is functional in PGS1-depleted cells.
Taken together, we conclude that PGS1 depletion can inhibit mito-
chondrial fragmentation by slowing mitochondrial fission in a
manner that is independent of OPA1 processing by OMA1.
PGS1 depletion improves SiMH without restoring basal fusion to
OPA1-deficient cells
To test whether PGS1 depletion also affected mitochondrial fusion
in Opa1Crispr MEFs, we assessed IMM fusion kinetics using a fluores-
cence recovery after photobleaching (FRAP) assay (Mitra &
Lippincott-Schwartz, 2010). Genetically encoded matrix-localized
YFP (mitoYFP) was photobleached in a subsection of mitochondria
and imaged 200 ms intervals (Fig 4F). In WT MEFs, mitoYFP single
increased ~ 2.5-fold in the photobleached region of the network
within a few seconds, demonstrating active mitochondrial fusion in
these cells. As expected, FRAP experiments performed under the
same conditions in Opa1Crispr MEFs revealed no significant recovery
of mitoYFP signal, indicating a block in mitochondrial fusion, which
was not improved upon additional deletion of Pgs1 (in Opa1CrisprPg-
s1Crispr MEFs) despite the appearance of a normal, tubular network
in these cells (Movies EV1–EV3). These results indicate PGS1
depletion does not restore basal mitochondrial fusion function to
Opa1Crispr MEFs.
Next, we sought to determine Opa1CrisprPgs1Crispr cells could
undergo mitochondrial elongation induced by SiMH, despite an inhi-
bition of IMM fusion. Live imaging of cells stimulated with CHX
(Fig 4F and G) or the transcriptional inhibitor Actinomycin D (ActD)
(Appendix Fig S6E and F) induced progressive mitochondrial hyper-
tubulation in both WT and Opa1CrisprPgs1Crispr MEFs, implying
normal hyperfusion capacity. These responses could be blunted in
Opa1CrisprPgs1Crispr MEFs by re-expression of PGS1 (Fig 4F and G,
Appendix Fig S6E and F), indicating that PGS1 activity inhibits SiMH
in OPA1-deficient cells. In Pgs1Crispr cells, we observed a more rapid
hypertubulation in response to SiMH than in WT MEFs
(Appendix Fig S6E and F). In hypomorphic Opa1Crispr MEFs, we also
observed a very modest but significant SiMH response, character-
ized by mitochondrial aggregation in Opa1Crispr MEFs in the pres-
ence of CHX (Fig 4F and G) or ActD (Appendix Fig S6E and F) and
stable re-expression of OPA1 fully rescued mitochondrial morphol-
ogy and SiMH response. MEFs devoid of any detectable OPA1
protein were unable to perform SiMH (Appendix Fig S4E and F)
consistent with previous reports (Tondera et al, 2009). Notably,
PGS1 depletion also failed to restore normal mitochondrial morphol-
ogy in Opa1KO MEFs (Fig EV5A and B) or Yme1lKO MEFs
(Fig EV5C–E), implying that the functional suppression of mito-
chondrial fragmentation by PGS1 depletion depends on the func-
tional severity. Thus, we conclude that PGS1 depletion can re-
establish SiMH response to Opa1Crispr MEFs without improving
mitochondrial fusion under basal condition. Altogether, our data
demonstrate that PGS1 depletion inhibits mitochondrial fragmenta-
tion in hypomorphic OPA1 mutant fibroblasts by inhibiting mito-
chondrial fission and not be increasing mitochondrial fusion.
Downregulation of cardiolipin synthesis pathway enzymes can
prevent mitochondrial fragmentation in OPA1-deficient cells
PGS1 synthetizes PGP from CDP-diacylglycerol (CDP-DAG) and
glycerol 3-phosphate (G3P) (Chang et al, 1998) (Fig 5A). PGP is
▸Figure 5. Interfering with the cardiolipin synthesis pathway can prevent mitochondrial fragmentation in OPA1-deficient fibroblasts.A Schematic of cardiolipin (CL) biosynthesis pathway in mitochondria. Phosphatidic acid (PA) is transported to the inner membrane by PRELID1 where it is converted to
CDP-diacylglycerol (CDP-DAG) and glycerol 3-phosphate (G3P) by TAMM41. Phosphatidylglycerol phosphate (PGP) is dephosphorylated to phosphatidylglycerol (PG) by
PTPMT1. PG is either degraded to DAG or reacts with CDP-DAG to form CL in a reaction catalyzed by cardiolipin synthase (CLS1). Tafazzin (TAZ) catalyzes the
remodeling of monolysocardiolipin (MLCL) to mature CL. CL is transported to the outer membrane and converted to PA by mitoPLD. PA is converted to DAG by LIPIN1.
PA can be supplied to the inner membrane from DAG conversion by Acylglycerol Kinase (AGK).
B Representative confocal micrographs of MEFs WT and Opa1Crispr MEFs treated with indicated siRNAs for 72 h. Mitochondria (anti-TOMM40, green) and nuclei (DAPI,
blue). Scale bar = 10 μm.
C Supervised ML mitochondrial morphology quantification of (B) using WT MEFs with fragmented (Opa1 siRNA), normal (non-targeting NT siRNA), and hypertubular
(Dnm1l siRNA) mitochondria. Data represent mean  SD of three independent experiments, One-way ANOVA (726–4,236 cells per cell line), (% fragmented);
***P < 0.001, ****P < 0.0001, ns; not significant.
D Quantitative RT–PCR (qRT–PCR) measurement of Prelid1, Tamm41, Pgs1, Ptpmt1, and Cls1 expression in Opa1Crispr and WT MEFs. Fold change is indicated relative to
WT control. Data represent mean  SD of three independent experiments, One-way ANOVA.
E Whole cell phospholipidome of WT and Opa1Crispr MEFs treated with NT (non-targeting), Tamm41 or Pgs1 siRNAs. Data represent mean  SD of five independent
experiments; *P < 0.05, ***P < 0.001, ****P < 0.0001, ns; not significant.
F Representative confocal micrographs of MEFs WT, Pgs1Crispr, and Dnm1lCrispr MEFs treated with indicated siRNAs for 72 h. Mitochondria (anti-TOMM40, green) and
nuclei (DAPI, blue). Scale bar = 10 μm.
G Supervised ML mitochondrial morphology quantification of (G) using WT MEFs with fragmented (Opa1 siRNA), normal (non-targeting NT siRNA), and hypertubulated
(Dnm1l siRNA) mitochondria. Data represent mean  SD of >3 independent experiments (3,096–7,238 cells per cell line), One-way ANOVA (% fragmented); *P < 0.05,
**P < 0.01, ****P < 0.0001, ns; not significant.
Source data are available online for this figure.
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dephosphorylated to phosphatidylglycerol (PG) by PTPMT1 (Zhang
et al, 2011), which is either degraded to DAG or reacts with CDP-
DAG to form CL in a reaction catalyzed by cardiolipin synthase,
encoded by Cls1 (Chen et al, 2006). Export of mature CL to the
OMM is subsequently converted by mitoPLD to phosphatidic acid
(PA), which inhibits fission by reducing DRP1 recruitment. PA can
also be converted to DAG by LIPIN1B to promote DRP1 recruitment
and mitochondrial fragmentation (Choi et al, 2006; Huang et al,
2011; Watanabe et al, 2011; Adachi et al, 2016). Since we observed
no alterations in DRP1 recruitment in PGS1-depleted cells (Fig 4A
and B) and PGS1 itself is an IMM enzyme, we decided to test
whether interfering with CL biosynthesis enzymes localized in the
IMM (Fig 5A) could reverse mitochondrial fragmentation of OPA1-
deficient fibroblasts. We performed a series of knockdown experi-
ments in WT and Opa1Crispr MEFs using siRNAs targeting genes
encoding enzymes both upstream (Prelid1, Tamm41) and down-
stream (Ptpmt1, Cls1) of Pgs1 and analyzed mitochondrial morphol-
ogy after 72 h (Fig 5B). Like the downregulation of Pgs1, we
discovered that acute, single depletion of Tamm41, Ptpmt1, or Cls1
could prevent mitochondrial fragmentation in Opa1Crispr MEFs
(Fig 5B and C). Opa1KO MEFs did not respond to Pgs1 or Tamm41
depletion: Mitochondrial morphology still remains fragmented upon
siRNA treatment (Fig EV5A and B). Prelid1 depletion lead to
increased mitochondrial fragmentation in both Opa1Crispr and WT
MEFs, confirming previous observations in HeLa cells (Potting et al,
2013). qRT–PCR analyses revealed significant transcriptional remod-
eling of CL enzymes in Opa1Crispr and WT MEFs (Fig 5D). Opa1Crispr
MEFs showed an upregulation of Prelid1, Tamm41, Pgs1, Ptpmt1,
and, to a greater extent, Cls1. Prelid1 depletion led to an upregula-
tion of Tamm41, Ptpmt1, and Cls1 concomitant with a reduction in
Pgs1 mRNA levels in both Opa1Crispr and WT MEFs. Tamm41 deple-
tion had more modest effects on the upregulation of Prelid1 and
Ptpmt1. Of note, Pgs1 depletion led to threefold to fivefold increases
in the levels of Tamm41, Ptpmt1, and Cls1 in WT MEFs but not in
Opa1Crispr MEFs. Similarly, Cls1 depletion led to similarly large
increases the levels of Prelid1, Tamm41, and Ptpmt1 mRNA in WT
MEFs but not in Opa1Crispr MEFs (Fig 5D), suggesting that there
may be underlying defects in CL responses in Opa1Crispr MEFs.
Depletion of either OPA1 or PGS1 reduces cardiolipin levels
We sought to determine the impact of OPA1 and PGS1 depletion on
the levels of CL. Quantitative phospholipidomic analyses of
Opa1Crispr MEFS revealed a reduction in CL content to 70.1  11.0%
of WT levels (Fig 5E). In addition, CL acyl chain composition analy-
ses showed an increase in double bonds (Appendix Fig S7A) and
altered acyl chain lengths (Appendix Fig S7B). Depletion via siRNA
treatment of WT MEFs for Pgs1 or, to a lesser degree, Tamm41
(Fig 5E) reduced the steady-state levels of CL to levels similar to
those of Opa1Crispr MEFs. Depletion of either Pgs1 or Tamm41 in
Opa1Crispr MEFs lead to a further depletion of CL levels but not
further alteration in acyl chain composition of CL. Overall, we found
no correlation between the levels or saturation state of CL and mito-
chondrial morphology, prompting us to consider the possibility that
suppression of PGS1 or TAMM41 in Opa1Crispr MEFs restores mito-
chondrial morphology not via a reduction in CL production but
rather through the accumulation of its precursor(s). The CL precur-
sor common to cells depleted of Tamm41, Pgs1, and Cls1 is PA,
which is first synthesized in the ER and shuttled from the OMM to
the IMM by the lipid transfer protein PRELID1 (Potting et al, 2013).
Suppression of PA delivery to the IMM via PRELID1 ablation causes
mitochondrial fragmentation. PA accumulation in the IMM affects
mitochondrial structure in yeast (Connerth et al, 2012), but its role
in mammalian mitochondria has not been defined. To test whether
local accumulation of PA in the IMM is responsible for the anti-
fragmentation effect of PGS1 depletion on mitochondrial morphol-
ogy, we pursued a genetic approach since lipid analyses of whole
mitochondria cannot be used to define the submitochondrial local-
ization of PA. We depleted Prelid1 in WT and Pgs1Crispr MEFs and
assessed mitochondrial morphology after 72 h (Fig 5F). Prelid1
depletion was able to fragment mitochondria in PGS1-deficient cells,
arguing that the IMM accumulation of PA resulting from a block in
the biosynthesis of CL (via PGS1 depletion) impedes mitochondrial
fission (Fig 5G). PRELID1 depletion did not fragment mitochondria
in DRP1-deficient (Dnm1lCrispr) MEFs, demonstrating that PA deple-
tion at the IMM promotes mitochondrial fragmentation in a DRP1-
dependent fashion, perhaps by increasing the accumulation of PA at
the OMM (Adachi et al, 2016). Taken together, these data argue that
IMM accumulation of the CL precursor PA but not CL itself is
responsible for the inhibition of mitochondrial fragmentation in a
DRP1-dependent manner.
PGS1 depletion does not alter apoptotic sensitivity nor cristae
dysmorphology caused by OPA1 depletion
OPA1 regulates cristae morphology and apoptosis in cultured cells
(Giacomello et al, 2020). To test whether restoration of mitochon-
drial morphology in Opa1Crispr Pgs1Crispr MEFs affects programmed
cell death, we stimulated MEFs with apoptosis-inducing compounds
and followed the evolution of cell death by live cell imaging (Figs
6A and B, and EV6A, Appendix Fig S8A and B). We kinetically
imaged thousands of cells (2,000–12,000) every hour over 24 h and
tracked NucBlue and propidium iodide (PI) as markers of total and
dead cells, respectively. In the presence of ABT-737 and Actino-
mycin D (ActD) cell death was triggered more rapidly in Opa1Crispr
cells compared with WT, which could be inhibited by the pan-
caspase inhibitor qVD. Opa1Crispr Pgs1Crispr MEFs exhibited cell
death profiles indistinguishable from Opa1Crispr MEFs, indicating
that rescued mitochondrial morphology does not protect against
apoptotic sensitivity caused by OPA1 depletion. In the presence of
staurosporine (Fig EV6A and B) or etoposide (Appendix Fig S8A and
B), Opa1Crispr Pgs1Crispr cell death sensitivity also did not return to
WT levels. Opa1Crispr cells exhibited reduced caspase-dependent cell
death in the presence of staurosporine or etoposide, confirming
previous observations of the stimuli-dependent apoptotic outcomes
of haploinsufficient OPA1-deficient MEFs (Kushnareva et al, 2016).
Notably, Pgs1Crispr cells exhibited increased apoptotic resistance
relative to WT cells when challenged with staurosporine, etoposide,
or ABT-737 and ActD.
To assess the impacts on mitochondrial ultrastructure, we
performed transmission electron microscopy on WT, Opa1Crispr
Pgs1Crispr, Opa1Crispr and Pgs1Crispr MEFs. WT cells exhibited IMMs
organized as lamellar cristae, which were disrupted as expected in
Opa1Crispr cells, which also had more rounded mitochondria consis-
tent with the fragmented network morphology previously described
(Fig 6C and D). However, IMM structure in Opa1Crispr Pgs1Crispr was
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not restored to WT morphology, despite a modest increase in cristae
number and OMM/IMM ratios, indicating that mitochondrial
morphology and cristae organization are largely uncoupled in these
cells. We did not detect cristae defects in Pgs1Crispr cells, implying
that CL reduction per se (Fig 5E) does cause defective mitochondrial
ultrastructure in mammalian cells. Taken together, our data demon-
strate that the role of OPA1 in balancing mitochondrial dynamics
can be uncoupled from its role as an organizer of IMM structure and
programmed cell death.
Rebalancing mitochondrial dynamics OPA1-deficient fibroblasts
through PGS1 improves bioenergetics but not mtDNA depletion
In order to analyze the functional impact of re-establishing a tubular
network on respiration and the oxidative phosphorylation
(OXPHOS) system, we measured oxygen consumption rates using
Seahorse FluxAnalyzer oxygraphy in intact MEFs depleted of OPA1
and/or PGS1 (Fig 7A). Opa1Crispr MEFs exhibited a modest reduction
in basal (Fig 7B) and maximal oxygen consumption rates (Fig 7C)
which could be improved upon deletion of PGS1 in Opa1CrisprPgs1Crispr
MEFs, implying that rebalancing mitochondrial dynamics posi-
tively impacts mitochondrial respiration. Oxygen consumption rate
(OCR) measurements performed using Seahorse FluxAnalyzer
requires that plated adherent cells be submitted to a brief period of
nutrient (glucose, CO2) deprivation, which has previously been
shown to induce mitochondrial hyperfusion (Gomes et al, 2011;
Khacho et al, 2014). To exclude the possibility that nutrient starva-
tion might confound bioenergetic measurements, we performed
high-resolution respirometry (O2k, Oroboros) on intact, nutrient-
replete MEFs in suspension (Fig EV7A). Opa1Crispr MEFs exhibited
reduced oxygen consumption, which was rescued either by func-
tional complementation with untagged OPA1 or depletion of PGS1.
Interestingly, functional complementation of oxygen consumption
and membrane potential defects present in Opa1Crispr MEFs was
possible only with untagged OPA1 (Figs 7A–C, and EV7A) and not
OPA1-Myc (Figs EV3G and H, and EV7B and C) even though both
tagged and untagged OPA1 constructs were able to restore mito-
chondrial morphology (Figs 3E and F, and EV3E and F). These data
further demonstrate that OPA1-dependent bioenergetic functions
can be uncoupled from mitochondrial dynamics, in this case using
a disruptive C-terminal epitope by the GED domain of the protein
(Mishra et al, 2014).
Importantly, Opa1CrisprPgs1Crispr MEFs exhibited increased basal
and maximal oxygen consumption rates relative to the parental
Opa1Crispr MEFs, which could be lowered back to levels similar to
Opa1Crispr MEFs by stable re-expression of PGS1 in Opa1Crispr
Pgs1Crispr MEFs. Pgs1-deficient cells exhibited increased respiration
using both Seahorse and Oroboros oxygen consumption assays
and were reduced upon re-expression of PGS1 (Figs 6A–C, and
EV7A–C).
Next, we sought to determine the effects of restored mitochon-
drial morphology in Opa1CrisprPgs1Crispr MEFs on mitochondrial
membrane potential. Cells were incubated with the potentiometric
dye tetramethylrhodamine ethyl ester (TMRE) to label actively
respiring mitochondria. TMRE signal intensity normalized to mito-
chondrial content (mitoYFP) and was recorded at the single-cell
◀ Figure 6. PGS1 depletion does not rescue apoptotic sensitivity nor cristae structure in OPA1-deficient MEFs.
A, B (A) MEFs of the indicated genotypes were subjected to 4 μM Actinomycin D and 10 μM ABT-737 in the presence or absence of the pan-caspase inhibitor qVD. Dead
cells (PI+ nuclei, orange) and total cells (NucBlue, blue) were imaged every hour for 25 h. PI+ nuclei number divided by the total nuclei number was then quantified
over time. (B) Representative confocal images of (A). Scale bar = 100 μm. Data represent mean  SD of three independent experiments (1,380–2,157 cells per cell
line), One-way ANOVA; ****P < 0.0001, ns; not significant.
C Representative transmission electron micrographs of MEFs of the indicated genotypes showing loss of lamellar cristae in Opa1Crispr and Opa1CrisprPgs1Crispr MEFs.
Scale bar = 200 nm.
D Quantification of (C) of mitochondrial ultrastructure; outer membrane/inner membrane ration (IMM/OMM) and cristae number per mitochondrion. Violin plot of
> 50 mitochondria per cell line, One-way ANOVA; *P < 0.05, ****P < 0.0001, ns; not significant.
Source data are available online for this figure.
▸Figure 7. PGS1 depletion enhances respiration in wild-type and OPA1-deficient MEFs.A–C (A) Mitochondrial respiration measured in adherent MEFs of the indicated genotypes using Seahorse FluxAnalyzer. Oxygen consumption rate (OCR) normalized to
protein concentration. Following basal respiration, cells were treated sequentially with 1 μM Oligomycin (Omy), 2 μM CCCP, Antimycin A 1 μM + 1 μM Rotenone.
Bar graphs of (A) representing basal (B) and maximum (C) respiration. Data represent mean  SEM of 7–12 independent OCR measurements, One-way ANOVA;
*P < 0.05, **P < 0.01, ***P < 0.001, ns; not significant.
D Mitochondrial membrane potential measured by fluorescence microscopy in WT, Opa1Crispr, Opa1Crispr + pLenti-Opa1, Opa1CrisprPgs1Crispr,
Opa1CrisprPgs1Crispr + pLenti-Pgs1, Pgs1Crispr, and Pgs1Crispr MEFs + pLenti-Pgs1. Membrane potential is represented as the ratio between TMRE/mitoYFP. WT MEFs
treated with 20 μM CCCP serve as a negative control for TMRE. Data represent mean  SD of three independent experiments, number of analyzed cells indicated
in inset, One-way ANOVA; **P < 0.01, ***P < 0.001, ****P < 0.0001, ns; not significant.
E mtDNA content in MEFs from (F) was quantified by amplification of Mtll1, 16s, and Mt-nd1 genes relative to the Gapdh nuclear gene in MEFs. Data represent
mean  SD of three independent experiments, One-way ANOVA; ****P < 0.0001, ns; not significant.
F mtDNA content in WT and mutant MEFs treated with indicated siRNAs for 72 h was quantified by amplification of Mttl1, 16s, and Mt-nd1 genes relative to the
GapdhH nuclear gene in MEFs. Data represent mean  SD of three independent experiments, One-way ANOVA; **P < 0.01, ****P < 0.0001, ns; not significant.
G, H (G) Equal amounts of protein extracted from WT and mutant MEFs were separated by SDS–PAGE (horizontal line denotes separate membranes), immunoblotted
with indicated antibodies, and quantified by densitometry (H). Data represent mean  SD of three independent experiments, One-way ANOVA; **P < 0.01,
***P < 0.001, ****P < 0.0001, ns; not significant.
Source data are available online for this figure.
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level using confocal fluorescence microscopy (Fig 7D). We observed
a reduction in membrane potential in Opa1Crispr MEFs that was
rescued upon stable re-expression of untagged OPA1 (Fig 7D).
Opa1CrisprPgs1Crispr MEFs exhibited a higher media membrane poten-
tial than Opa1Crispr MEFs but lower than that of WT cells measured
by microscopy (Fig 7D). Thus, rescuing mitochondrial morphology
of Opa1Crispr MEFs via PGS1 depletion improves mitochondrial
respiration and membrane potential.
qPCR measurement of mitochondrial DNA (mtDNA) content
using primer pairs targeting different regions of mtDNA revealed a
depletion of mtDNA in Opa1Crispr MEFs, which was not rescued by
PGS1 depletion by Crispr/Cas9-mediated ablation (Opa1CrisprPg-
s1Crispr MEFs) or siRNA depletion (Fig 7E and F). These data demon-
strate that mitochondrial fragmentation and mtDNA maintenance
defects in OPA1-deficient cells can be uncoupled.
To assess the impact of rebalancing mitochondrial dynamics on
the oxidative phosphorylation (OXPHOS) complexes, we measured
the levels of structural subunits by Western blot analyses (Fig 7G).
Opa1Crispr MEFs showed reduced levels of NDUFA9 (Complex I),
SDHA (Complex II), UQCRC2 (Complex III), MT-CO2 (Complex IV),
and ATP5B (Complex V). Additional depletion of Pgs1 in Opa1Crispr
Pgs1Crispr MEFs could rescue the levels of SDHA, UQCRC2, and
ATP5B, but not of NDUFA9 nor MT-CO2, which belong to the two
respiratory complexes that derive the most structural subunits from
mtDNA (Fig 7H). Consistent with elevated membrane potential
measured (Fig EV4F) and mtDNA content (Fig 7E) in Pgs1Crispr cells,
we observed an increase in oxygen consumption rates relative to
WT MEFs, which could be lowered by functional complementation
with re-expression of PGS1. Altogether, our data demonstrate func-
tional amelioration of OXPHOS and bioenergetic defects in OPA1-
deficient cells by depleting PGS1.
Discussion
In this study, we present a new imaging approach using supervised
machine learning to classify mitochondrial morphology of human
and mouse fibroblasts according to pre-defined categories represent-
ing unopposed fusion and fission. This classification strategy is
robust and can reproducibly recognize mitochondrial fragmentation
induced either by accelerated fission or blocked fusion resulting
from genetic or chemical manipulation without introducing user
bias (Fig EV1, Appendix Fig S1A and B). Importantly, this workflow
is highly scalable and robust at all levels, as evidenced by its appli-
cation to automated, high-throughput phenotypic screens performed
in human fibroblasts using the Mitome siRNA library (Fig 2A and
D). This classification approach is relative and based on ground
truths for mitochondrial morphologies generated by siRNA-
mediated depletion of known fission or fusion genes, which are
measured and applied at each image acquisition experiment. This
compensates for the variability in mitochondrial morphologies
generated due to experimental reasons (e.g., cell culture conditions,
cell density, gas levels) and intrinsic population heterogeneity. We
applied this unbiased strategy to classify mitochondrial morphology
in an array of skin fibroblasts derived from patients suffering from
Dominant Optic Atrophy plus (DOA+) and discovered that not all
pathogenic variants in OPA1 trigger mitochondrial fragmentation,
despite patients belonging to the same clinical grouping (Table 1).
Neither the steady-state levels of OPA1 protein in fibroblasts
(Appendix Fig S2D) nor the clinical manifestation could predict the
p.Ser545Arg and p.Arg445His GTPase domain missense variants to
be most phenotypically severe with respect to mitochondrial
morphology (Fig 1B and C). While the molecular explanation for
this discordance remains unexplained, we posit that additional
factors may modulate mitochondrial morphology in patient fibrob-
lasts. Yet to our knowledge no known genetic modifiers of disease
genes involved in mitochondrial dynamics, including OPA1-related
diseases have yet been identified. Within OPA1, genotype-
phenotype relationships can be loosely established but it is not
possible to fully predict clinical outcome for DOA and DOA+
patients solely based on the location and nature of pathogenic,
mono-allelic variants in OPA1. Recently, intra-allelic variants of
OPA1 have been documented to modify clinical and biochemical
phenotypes in DOA+ (Bonifert et al, 2014), indicating that genetic
modulation of OPA1 and its function(s) is formally possible. More-
over, chemically induced mitochondrial dysfunction in epithelial
cells can be buffered by loss of function of other metabolic genes
(To et al, 2019), arguing for the existence of genetic modifiers of
MD beyond OPA1. To seek out genetic modifiers of mitochondrial
morphology, we coupled our mitochondrial morphology imaging
and quantification workflow to a bespoke siRNA library targeting
the entire mitochondrial proteome (Mitome) and identified known
and novel genes whose depletion promoted mitochondrial fragmen-
tation (Fig 2B) or hypertubulation (Fig 2C) in control fibroblasts as
well as 91 genes whose depletion could rescue mitochondrial frag-
mentation in OPA1 mutant patient-derived fibroblasts. As such,
these data provide a valuable resource for further investigation of
the genetic regulation of mitochondrial dynamics. We discovered
that several of the genes capable of reversing mitochondrial frag-
mentation in OPA1 mutant cells with the most severely fragmented
mitochondrial network (Fig 2D) also led to hypertubulation in
control fibroblasts (Fig 2F), including known components of the
mitochondrial fission apparatus (DNM1L, MIEF1, MFF, SLC25A46),
which demonstrates in patient fibroblasts that imbalanced mito-
chondrial dynamics can be genetically re-equilibrated, as previously
documented in animal models of MD (Chen et al, 2015; Wai et al,
2015; Yamada et al, 2018). Mitome screening also identified a clus-
ter of ribosomal genes, whose individual depletion would be
predicted to impair protein synthesis. Indeed, we can show that
treating human OPA1S545R or mouse Opa1Crispr fibroblasts with CHX
can promote stress-induced mitochondrial hyperfusion (SiMH).
SiMH can be promoted by inhibition of transcription (Appendix Fig
S6E), translation (Fig 4F), as well as the induction of ER stress (Ton-
dera et al, 2009; Morita et al, 2017; Lebeau et al, 2018). We discov-
ered CALR, which encodes a highly conserved chaperone protein
that resides primarily in the ER involved in ER stress responses to
be a suppressor of mitochondrial fragmentation (Dataset EV4, Fig 2
F). Finally, we also discovered an array of nuclear-encoded mito-
chondrial genes that rescued mitochondrial fragmentation but that
had not previously associated with mitochondrial dynamics. These
genes cover various classes of mitochondrial functions including
mitochondrial gene expression, oxidative phosphorylation, and
amino acid metabolism yet how these genes (Dataset EV4) or
processes (Fig EV2H, Appendix Fig S3A) influence mitochondrial
dynamics is unclear and warrants further investigation. Intriguingly,
a substantial proportion of these genes are found to be mutated in
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inborn errors of metabolism (Dataset EV4), yet the effects on mito-
chondrial morphology have not yet been explored. Altogether, our
results demonstrate that it is possible to apply an unbiased, high-
throughput imaging approach to identify candidate suppressors of
mitochondrial dysfunction in MD patient fibroblasts.
We discovered PGS1 depletion could restore mitochondrial
morphology to hypomorphic OPA1 patient-derived fibroblasts and
mouse embryonic fibroblasts (MEFs) mutated for Opa1 as well as
OPA1-deficient HeLa cells (Appendix Fig S3A–C). This occurred via a
reduction in mitochondrial fission that was independent of both the
recruitment of DRP1 to mitochondria (Fig 4A and B) and OMA1-
dependent proteolytic processing of OPA1, which are key steps in
pathological and physiological fission (Giacomello et al, 2020). Simi-
lar to DRP1 or OMA1 ablation, PGS1 depletion can protect from induc-
tion of stress-induced fission and fragmentation triggered by chemical
agents known to promote OMA1-dependent OPA1 processing and/or
DRP1 recruitment, thereby implicating PGS1 in mitochondrial fission.
The notion that impairing PGS1 and thus CL biogenesis might
rescue mitochondrial morphology defects caused by OPA1 defects
seem counterintuitive at first, given existing reports of a require-
ment of CL on opposing membranes for OPA1-mediated fusion (Ban
et al, 2017). Opa1CrisprPgs1Crispr MEFs exhibit a similar block of IMM
fusion as Opa1Crispr MEFs and it is therefore not possible to assess
the contribution of CL for mitochondrial fusion. Nevertheless,
several observations exclude CL depletion as a mechanism for
restored mitochondrial morphology in hypomorphic OPA1-deficient
cells. First, lipidomic analyses of Opa1Crispr MEFs revealed a deple-
tion and alteration of CL acyl chain composition, neither of which
was restored by additional depletion of either Pgs1 or Tamm41
(Fig 5E) even though mitochondrial morphology was restored in
these cells. In fact, TAMM41 or PGS1-depleted Opa1Crispr MEFs
exhibit even lower steady-state CL levels than Opa1Crispr MEFs
(Fig 5E) and unaltered CL saturation states (Appendix Fig S7A).
Second, WT MEFs depleted of either PGS1 or TAMM41 show
reduced CL levels similar to Opa1Crispr MEFs but without an induc-
tion of mitochondrial fragmentation (Fig 5B and C). Third, inhibi-
tion of cardiolipin synthase (CLS1) does not cause mitochondrial
fragmentation but rather promotes mitochondrial elongation (Fig 5
B) (Matsumura et al, 2018). Fourth, depletion of the CL remodeling
enzyme Tafazzin (TAZ1), does not impair mitochondrial fusion nor
trigger mitochondrial fragmentation (Ban et al, 2018). Finally, the
inhibition of fission mediated by PGS1 depletion can be reversed by
additional suppression of PRELID1, which is upstream in the CL
biosynthesis pathway (Fig 5A) and is needed to deliver PA to the
IMM. PRELID1 inhibition prevents the delivery of PA to the IMM
(Connerth et al, 2012), which is normally converted to CDP-DAG
and PGP by TAMM41 and PGS1, respectively (Tamura et al, 2020).
In yeast, the deleterious effect of PA accumulation in the IMM is
supported by observations that altered mitochondrial structure in
pgs1 mutant cells, which accumulate PA in the IMM, can be rescued
by additional deletion of the Prelid1 orthologue Ups1(Connerth
et al, 2012). We therefore propose that the accumulation of PA
rather the depletion of CL drives the suppression of mitochondrial
morphology defects caused by OPA1 dysfunction.
From a functional perspective, restoration of mitochondrial
morphology in OPA1-deficient MEFs rescued respiration but not
cristae dysmorphology, apoptotic sensitivity, CL dysregulation nor
mtDNA depletion observed in Opa1Crispr MEFs. The programmed
cell death response manifested by Opa1CrisprPgs1Crispr MEFs was
similar to that of Opa1Crispr MEFs when treated with apoptotic
inducers, indicating the mitochondrial morphology alone does not
dictate cell death sensitivity. Disruption of IMM architecture in
OPA1 deficiency has recently been linked to the stability of the
MICOS complex (Stephan et al, 2020) but whether CL deficiency
contributes to cristae dysmorphology in these cells is unclear. Inter-
estingly, the Mitome screen in OPA1S545R fibroblasts identified
DNAJC4, DNACJ11, and MTX1; interactors of the MICOS complex,
which is known to facilitate intramitochondrial lipid transport (Aal-
tonen et al, 2016, 35). In yeast, mitochondria lacking pgs1 exhibit
altered cristae structure, characterized by extremely elongated
cristae sheets resembling onion-like structures (Connerth et al,
2012). However, in MEFs, depletion of Pgs1Crispr reduces CL levels
without an observable impact on cristae, arguing that CL depletion
alone is not sufficient to cause cristae loss in mammalian cells.
The notion that balanced mitochondrial dynamics is critical for
cellular health arises from the observations that dampening of mito-
chondrial fission confers physiological benefits in animal models of
mitochondrial dysfunction characterized by mitochondrial fragmen-
tation (Xiao et al, 2014; Wai et al, 2015; Xie et al, 2015; Acin-Perez
et al, 2018; Yamada et al, 2018) but whether this paradigm is appli-
cable to human disease has never been investigated. However, the
relevance of existing genetic targets of mitochondrial fission is
limited due to the essential nature of these genes. For DRP1, whole-
body ablation of Dnm1l in mice causes embryonic lethality and
tissue-specific deletion in organs most critically affected in MD is
crippling. Moreover, loss-of-function variants in DNM1L or genes
involved in DRP1-dependent fission including MIEF1 (Charif et al,
2021), SLC25A46 (Abrams et al, 2015, 46), MFF (Koch et al, 2016),
GDAP1 (Baxter et al, 2002), and INF2 (Boyer et al, 2011) all-cause
severe neurodegenerative diseases, making them unlikely therapeu-
tic targets. The Mitome screen in OPA1S545R fibroblasts identified a
cluster of cytosolic ribosomal genes, whose individual depletion
would be predicted to impair protein synthesis. These findings are
consistent with the observation that treatment of OPA1S545R patient
fibroblasts with the cytosolic protein synthesis inhibitor CHX can
suppress mitochondrial fragmentation in both OPA1S545R patient-
derived fibroblasts (Fig 1F) and hypomorphic Opa1Crispr MEFs
(Appendix Fig S4C and D), although pharmacological inhibition of
global protein synthesis does not represent a viable therapeutic
strategy to rescue defects in mitochondrial form and function. PGS1
depletion does not appear to incur cellular dysfunction in vitro, yet
future studies are needed to determine the physiological relevance
of this gene and whether it will serve as a useful modulator of mito-
chondrial function in vivo. In the meantime, we believe it worth-
while to consider PGS1 and other genetic modifiers that we have
identified using our Mitome screening approach when evaluating
the genetic and phenotypic landscape of OPA1-related diseases.
Materials and Methods
Human skin fibroblasts
Primary fibroblast cultures obtained from patients suffering from
DOA+ carrying mono-allelic pathogenic variants in OPA1
(OPA1S545R, OPA1R445H, OPA1Q297X, OPA1I432V, OPA1c.2356-1G>T) and
ª2021 The Authors EMBO Molecular Medicine e13579 | 2021 19 of 29
Emma Cretin et al EMBO Molecular Medicine
healthy individuals with no signs of optic atrophy (CTL-1, CTL-2,
CTL-3), which served as controls, were established as previously
described (Amati-Bonneau et al, 2005; Kane et al, 2017) and
described in Table 1. Written, informed consent was obtained from
all human subjects. The experiments conformed to the principles set
out in the WMA Declaration of Helsinki and the Department of
Health and Human Services Belmont Report. Approval for research
was granted by the Ethics Committee of the University Hospital of
Angers (Comite de Protection des Personnes CPP Ouest II—Angers,
France; Identification number CPP CB 2014/02; Declaration number
DC-2011-1467 and Authorization number AC-2012-1507); and the
Yorkshire and the Humber—Bradford Leeds Research Ethics
Committee (REC reference: 13/YH/0310). OPA1 variants are
described according to the OPA1 transcript variant 1 (RefSeq:
NM_015560.2) and variant 8 (RefSeq: NM_130837.2) in Table 1.
Compared with transcript variant 1 (RefSeq: NM_015560.2), the
original transcript identified, transcript variant 8, based on an alter-
nate splice pattern that contains two additional exons, 4b and 5b
(Delettre et al, 2001). However, it maintains the same reading frame
encoding an isoform (8) of 1,015 amino acids (aa). To maintain
historical compatibility, variants are also described in the article
according to transcript variant 1. The numbering of the nucleotides
reflects that of the cDNA, with “+1” corresponding to the “A” of the
ATG translation initiation codon in the reference sequence, accord-
ing to which the initiation codon is codon 1, as recommended by
the version 2.0 nomenclature of the Human Genome Variation Soci-
ety (HGVS; http://varnomen.hgvs.org) (Dunnen et al, 2016).
Following the HGVS guidelines, deduced changes are indicated
between brackets.
Mouse embryonic fibroblasts
Mouse embryonic fibroblasts (MEF) expressing mitochondrially
targeted YFP (mitoYFP MEF) were isolated from Gt(ROSA26)Sormi-
toYFP/+ embryos on a C57Bl6/N genetic background at E13.5 and
immortalized using a plasmid encoding SV40 large T antigen as
previously described (Anand et al, 2014). Wild-type and Yme1l−/−
(YKO) MEFs lacking mitoYFP (MEF1 WT) expression were gener-
ated from Yme1lLoxp/LoxP embryos on a C57Bl6/N genetic as previ-
ously described (Anand et al, 2014). MEFs lacking MiD49/MiD51/
Mff generated as previously described (Osellame et al, 2016) were a
gift from Dr. Michael Ryan.
Plasmids
Complementary DNA (cDNA) encoding mouse Pgs1 with a C-
terminal Myc tag and Opa1 with a C-terminal 9X Myc tag (pclbw-
opa1(isoform 1)-myc; a gift from David Chan [Addgene plasmid #
62845]) (Mishra et al, 2014) were cloned into pDONR-221 and then
pLenti6/Ubc (Invitrogen) using Gateway Technology (Invitrogen).
Generation of an Opa1 isoform 1 construct lacking the C-terminal
Myc tag was achieved by site-directed mutagenesis. MitoTAG
constructs pMXs-3XHA-EGFP-OMP25 (a gift from David Sabatini
[Addgene plasmid # 83356]) and pMXs-3XMyc-EGFP-OMP25 (a gift
from David Sabatini [Addgene plasmid # 83355]) were used for
mitochondrial immunocapture studies. pCMV-mRFP-PASS and
pCMV-mRFP-PASS-4E plasmids (Zhang et al, 2014) used for PA
localization studies were a kind gift from Dr. Guangwei Du.
Cell culture conditions
Primary human fibroblasts were cultured in growth media:
Dulbecco’s modified Eagle’s medium (DMEM) containing 4.5 g/l D-
Glucose, GlutaMAX™ and pyruvate supplemented with 10% Fetal
Bovine Serum (FBS) and 50 μg/ml penicillin/streptomycin (P/S) in
a 5% CO2 atmosphere at 37°C and used at passages between 10 and
15. MEFs were cultured in growth media: DMEM containing 4.5 g/l
D-Glucose, GlutaMAX™ and pyruvate supplemented with 5% FBS
and 50 μg/ml P/S in a 5% CO2 atmosphere at 37°C. Cells were routi-
nely tested for Mycoplasma by PCR.
Generation of OPA1-, PGS1-, and DRP1-deficient and DRP1 KI
cell lines
Genetic disruption of Opa1, Pgs1, and Dnm1l (Drp1) in MEFs was
performed via CRISPR-Cas9 gene editing. The single-guide RNAs
(sgRNAs) were designed using the CRISPR-Cas9 design tool from
Benchling (https://www.benchling.com/crispr/) and for Exon 4 of
Opa1 (sgRNA: forward: 50-caccgTGCCAGTTTAGCTCCCGACC-30 and
reverse: 50-aaacGGTCGGGAGCTAAACTGGCAc-30) and Exon 2 of
Pgs1 (sgRNA: forward: 50-caccgTATGTCCCGAGGGTGTACAC-30 and
reverse 50-aaacGTGTACACCCTCGGGACATAc-30), and Exon 1 of
Dnm1l (sgRNA: forward: 50 caccgGCAGGACGTCTTCAACACAG-30
and reverse 50-aaacCTGTGTTGAAGACGTCCTGCc-30). sgDNA
oligonucleotides were annealed and cloned into the BbsI digested
pSpCas9(BB)-2A-GFP vector (SpCas9(BB)-2A-GFP (PX458) was a
gift from Feng Zhang (Addgene plasmid # 48138). MEFs were trans-
fected with 5 μg of pSpCas9(BB)-2A-GFP plasmid containing the
respective sgRNA using Lipofectamine 3000 (Life Technologies,
L3000008). After 24 h incubation, GFP-positive cells were individu-
ally isolated by fluorescence-activated cell sorting. Clones were
expanded and were validated by Western blotting, Sanger sequenc-
ing, Illumina MiSeq PE300 deep sequencing of PCR amplicons
generated using primers in Dataset EV5. Crispr/Cas9-mediated
knock-in of mTurquoise2 into the Dnm1l locus directly downstream
of the start codon was performed using a plasmid encoding mTur-
quoise 2 flanked by 723 bp of upstream and 696 bp of downstream
homologous DNA sequence cloned into pEX-A258 to create plasmid
pTW306 (pEX-A258-Turq2_mDNM1L_mut). Two pairs of sgDNA
targeting Dnm1l (sgDNA1: forward 50-caccgCCGGGATCAGCGCC
TCCATGACC-30 and reverse 50-GGTCATGGAGGCGCTGATCCCGGc-
30, sgDNA2: forward 50-caccgAGCAGGCCACTGCAATGAATGGG and
reverse 50-CCCATTCATTGCAGTGGCCTGCTc-30) were cloned into
pSpCas9n(BB)-2A-Puro (PX462) V2.0 (a gift from Feng Zhang
(Addgene plasmid # 62987) to generated plasmids pTW305
(pSpCas9n(BB)-DNM1L sgDNA 1_TW662_663_2A-Puro (PX462)
V2.0) and pTW307 (pSpCas9n(BB)-DNM1L sgDNA 2_TW664_665_2A-
Puro (PX462) V2.0), respectively. MitoYFP WT and Opa1Crispr MEFs
were transfected with 4 μg of plasmids (1 μg each of pTW305 and
pTW307 and 2 μg of pTW306 linearized with EcoRV) using
Lipofectamine 3000 (Life Technologies, L3000008). After 24 h incu-
bation, mTurquoise-positive, YFP-positive cells were individu-
ally isolated by fluorescence-activated cell sorting. Clones were
expanded and were validated by PCR genotyping of genomic DNA
using primers in Dataset EV5 and confocal imaging.
Genetic disruption of OPA1 in HeLa cells was performed via
CRISPR-Cas9 gene editing targeting Exon 17 of OPA1 (sgRNA:
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forward: 50-caccgAAAAGCAGTCTGATACTGCA-30 and reverse: 50-
aaacTGCAGTATCAGACTGCTTTTc-30). sgDNA oligonucleotides
were annealed and cloned into the BbsI digested pLentiCRISPRv2
(Addgene plasmid # 52961). HeLa cells were transfected with 5 μg
of pLentiCRISPRv2 (Addgene plasmid # 52961) plasmid containing
the respective sgRNA using Lipofectamine 3000 (Life Technologies,
L3000008). After 24 h incubation in puromycin, cells were individu-
ally isolated by cytometry. Clones were expanded and were vali-
dated by western blotting, Sanger sequencing. OPA1CRISPR HeLa
cells carry a heterozygous 19bp deletion causing a nonsense muta-
tion (c.1763delTGCTTTTGGAAAATGGTAC, p.Glu637* mutation).
Lentiviral and retroviral transductions
Lentiviral particles were generated from the following plasmids:
pLenti6/Ubc-Opa1-9xMyc, pLenti6/Ubc-Opa1, pLenti6/Ubc-Pgs1,
pMXs-3XHA-EGFP-OMP25, and pMXs-3XMyc-EGFP-OMP25. VSV-G-
pseudotyped vectors were produced by transient transfection of
293T cells with a packaging construct, a plasmid producing the
VSV-G envelope (pMD.G) and pBA-rev and pHDMH-gpM2 plasmids.
Culture medium was collected at 24, 48, and 72 h, pooled, concen-
trated approximately 1,000-fold by ultracentrifugation, aliquoted,
and stored at −80°C until used. Vector titers were determined by
FACS cell Sorting on infected HCT116 cells infected with serial dilu-
tions of vector stock. Transduction of MEFs was performed as previ-
ously described (Wai et al, 2016).
Mitochondrial morphology imaging
Human Fibroblasts Cells were seeded on CellCarrier-384 or 96well
Ultra microplate (PerkinElmer) and incubated for at least 24 h in
growth media. Fibroblasts were fixed with 4% PFA-PBS (w/v) for
15 min, permeabilized in 0.1% (v/v) Triton X-100-PBS for 10 min,
and blocked in 10% FBS-PBS overnight at 4°C. The following day,
permeabilized cells were first stained with the primary antibody
anti-TOM40 (diluted 1:1,000 in 5% FBS-PBS), washed three times
with PBS, and then incubated with fluorescently coupled secondary
antibody Alexa Fluor 488. Nuclei were finally marked with DAPI
(1:10,000 in PBS). Images were acquired using the Operetta CLS
High-Content Analysis System (PerkinElmer), with 40× Air/0.6 NA
or 63× Water/1.15 NA. Alexa Fluor 488 and DAPI were excited with
the 460–490 and 355–385 nm LEDs, respectively.
MEFs Cells were seeded on 96well CellCarrier Ultra imaging
plates (PerkinElmer) 24 h before imaging. Nuclei were labeled with
NucBlue™ Live ReadyProbes™ Reagent (Thermo Fisher Scientific).
Fluorescent labeling of mitochondria was achieved using Tetram-
ethylrhodamine Ethyl Ester Perchlorate (TMRE) and/or MitoTracker
Deep Red at 100 nM for 30 min at 37°C, 5% CO2 and/or with geneti-
cally encoded mitochondrially targeted YFP (mitoYFP). Spinning
disk confocal images were acquired using the Operetta CLS or Opera
Phenix High-Content Analysis systems (PerkinElmer), with 20×
Water/1.0 NA, 40× Air/0.6 NA, 40× Water/1.1 NA or 63× Water/
1.15 NA. YFP (460–490 nm), TMRE (530–560 nm), MitoTracker
Deep Red (615–645 nm), mTurquoise2 (435–460 nm), and DAPI
(355–385 nm) were excited the appropriate LEDs (Operetta CLS) or
lasers (Operetta Phenix). FRAP experiments were performed with a
Nikon Ti2E spinning disk microscope 60× Oil objective/NA1.4
equipped with a Photometrics Prime 95b cMOS camera (pixel
11um). Photobleaching was performed with a 405 laser at (35%
power, 400 ms dwell time) and image collection proceeded immedi-
ately thereafter at 200 ms intervals. Quantification FRAP studies
was performed using Fiji (ImageJ).
SDS–PAGE immunoblot analysis
Cells were lysed in ice-cold RIPA buffer (50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 1%(v/v) Triton X-100, 0.1% SDS, 0.05% sodium
deoxycholate, 1 mM EDTA, and complete protease inhibitor cocktail
mix (Roche)). After 30 min of incubation on ice, lysates were centri-
fuged at 16,000 g for 10 min at 4°C. Protein quantification of the
cleared lysates was performed by Bradford colorimetric assay
(Sigma) using a BSA standard curve. Absorption was measurement
at 595 nm by the microplate reader Infinite M2000 (TECAN). 15 μg
of each sample was reduced and negatively charged with 4X
Laemmli Buffer (355 mM 2-mercaptoethanol, 62.5 mM Tris–HCl pH
6.8, 10% (v/v) glycerol, 1% (w/v) SDS, 0.005% (v/v) Bromophenol
Blue). Samples were heated 5 min at 95°C and separated on 4–20%
Mini-PROTEAN® TGX Stain-Free™ Precast gels (Bio-Rad) or on
home-made 7% polyacrylamide gel for OPA1 immunodetection.
Gels were then transferred to nitrocellulose membranes with Trans-
Blot® Turbo™ Transfer system (Bio-Rad). Equal protein amount
across membrane lanes was checked by Ponceau S staining or Stain-
free detection. Membranes were blocked for 1 h with 5% (w/v)
semi-skimmed dry milk dissolved in Tris-buffered saline Tween
0.1% (TBST), incubated overnight at 4°C with primary antibodies
dissolved 1:1,000 in 2% (w/v) Bovine Serum Albumin (BSA), 0.1%
TBST. The next day membranes were incubated at least 1 h in
secondary antibodies conjugated to horseradish peroxidase (HRP) at
room temperature (diluted 1:10,000 in 5% milk). Finally,
membranes were incubated in Clarity™ Western ECL Substrate (Bio-
Rad) for 2 min and luminescence was detected using the
ChemiDoc® Gel Imaging System. Densitometric analysis of the
immunoblots was performed using Image Lab Software (Bio-Rad).
siRNA transfection
Silencing of the indicated genes was performed using forward trans-
fection: 20 nM of the specific siRNA was mixed with Lipofectamine
RNAiMax (Invitrogen), added on top of seeded cells, and left at 37°C
in a CO2 incubator for 72 h. Specific and non-targeting siRNAs were
obtained from Dharmacon. For mouse siRNA: Negative control NT:
D-001210-04-05; Opa1 siRNA: L-054815-01-0005, Drp1 siRNA: L-05
4815-01-0005, Pgs1 siRNA: L-064480-01-0005, Tamm41 siRNA: M-
056928-01-0005, Ptpmt1 siRNA: M-047887-01-0005, Cls1 siRNA: M-
055736-01-0005, Prelid1 siRNA: M-065330-01-0005. For human
siRNA: Negative control NT: D-001210-04-05, PGS1 siRNA: D-009
483-02-0002 + D-009483-13-0002 + D-009483-01-0002 + D-009483-
04-0002; TAMM41 siRNA: L-016534-02-0005; DNM1L siRNA: M-
012092-01- 0005; OPA1 siRNA: M-005273-00- 0005; DNAJC11 siRNA:
D-021205-03-0002; DNAJC4 siRNA: D-020055-17-0002.
RT–qPCR
Total RNA was extracted using TRIzol™ Reagent and chloroform,
purified, and subjected to DNA digestion using the NucleoSpin RNA
kit (MACHEREY-NAGEL). RNA concentration was measured using
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NanoQuant Plate™ (Infinite M200, TECAN), and 1 μg of total RNA
was converted into cDNA using the iScript Reverse Transcription
Supermix (Bio-Rad). RT–qPCR was performed using the CFX384
Touch Real-Time PCR Detection System (Bio-Rad) and SYBR® Green
Master Mix (Bio-Rad) using the primers listed in Table 3. Actin or
APP were amplified as internal standards. Data were analyzed
according to the 2ΔΔCT method (Livak & Schmittgen, 2001).
Analysis of oxygen consumption rates
Oxygen consumption was measured with the XFe96 Analyzer (Sea-
horse Biosciences) and High-Resolution Respirometry (O2k-
Fluorespirometer, Oroboros, AT). For Seahorse experiments, cells
(30,000 MEFs or 20,000 human fibroblasts experimentally optimized)
were seeded onto 96-well XFe96 cell culture plates. On the following
day, cells were washed and incubated with Seahorse XF Base Medium
completed on the day of the experiment with 1 mM Pyruvate, 2 mM
Glutamine, and 10 mM Glucose. Cells were washed with the Seahorse
XF Base Medium and incubated for 45 min in a 37°C non-CO2 incuba-
tor before starting the assay. Following basal respiration, cells were
treated sequentially with: oligomycin 1 µM, CCCP 2 µM and Anti-
mycin A 1 µM + 1 µM Rotenone (Sigma). Measurements were taken
over 2-min intervals, proceeded by a 1-min mixing and a 30 s incuba-
tion. Three measurements were taken for the resting OCR, three for
the non-phosphorylating OCR, three for the maximal OCR, and three
for the extramitochondrial OCR. After measurement, the XFe96 plate
was washed with Phosphate-Buffered Saline (PBS) and protein was
extracted with RIPA for 10 min at room temperature. Protein quantity
in each well was then quantified by Bicinchoninic acid assay (BCA).
Absorption was measurement at 562 nm by the microplate reader
(Infinite M200, TECAN) and used to normalize OCR data.
For O2k respirometry, 2 million intact MEFs were transferred to
the 37°C-heated oxygraph chambers containing MiRO5 buffer. Basal
respiration was measured first. Then, 10 nM oligomycin, 2 µM
CCCP, and 25 µM AntimycinA + 5 µM Rotenone were sequentially
injected, and non-phosphorylating OCR, maximal OCR, and extrami-
tochondrial OCR were measured, respectively. Finally, cells were
recovered and washed once with PBS. Protein was extracted with
RIPA Buffer for 30 min at 4°C and quantified using Bradford assay.
Absorption was measurement at 595 nm by the microplate reader
(Infinite M200, TECAN) and used to normalize O2 flux.
mtDNA content quantification
Genomic DNA was extracted using the NucleoSpin Tissue
(MACHEREY-NAGEL) and quantified with NanoQuant Plate™ (Infinite
M200, TECAN). RT–qPCR was performed using the CFX384 Touch
Real-Time PCR Detection System (Bio-Rad), 25 ng of total DNA, and
the SYBR® Green Master Mix (Bio-Rad). Actin or APP was amplified as
internal standards. Primers sequence are listed in Table 3. Data were
analyzed according to the method (Livak & Schmittgen, 2001).
Mitochondrial morphology quantification
Harmony Analysis Software (PerkinElmer) was used for automated
image analysis as described in detail in Table 3 PhenoLOGIC
sequence. Z-projected images first undergo brightfield correction.
Nuclei and cellular segmentation were defined using the “Find
Nuclei” building block with the HOECHST 33342 channel and the
“Find Cytoplasm” building block with the Alexa 488 or TMRE (mito-
chondria) channel. Mitochondrial network was analyzed using SER
Texture properties (Ridge, Bright, Edge, Dark, Valley, Spot), and the
PhenoLOGIC supervised machine learning algorithm was used to
identify the best properties able to segregate the three populations:
“Normal”, “Fragmented” and “Hypertubulated” network. ~ 200–400
cells of each control (Normal: WT + DMSO or WT + NT siRNA,
Fragmented: WT + CCCP or WT + OPA1 or Opa1 siRNA, Hyper-
tubulated: WT + CHX or WT + DNM1L or Dnm1l siRNA) were
selected to feed the algorithm for training. Automatic single-cell
classification of non-training samples (i.e., unknowns) was carried
out by the supervised machine learning module.
High-content screening
The siRNA library (Mitome; 1,531 siRNAs) consists of a Cherrypick
SmartPool siRNA library targeting all known and predicted mito-
chondrial genes based on Mitominer V4 and Mitocarta. 500 nl of
2 µM siRNAs (20 nM final concentration) were distributed on 6 dif-
ferent 384-well imaging plates (CellCarrier Ultra, PerkinElmer), as
described in Table 3, using Echo 550 (Labcyte Inc.) and were left to
dry under a sterile hood at least for 24 h. For each well, 10 µl of PBS
containing 0.1 µl of Lipofectamine RNAiMax was automatically
added using the pipetting robot VIAFLO 384 (Integra). After 1 h
incubation at room temperature (RT), 2,000 OPA1S545R patient
fibroblasts (in 40 µl) were added to each well for reverse transfec-
tion using the VIAFLO 384 (Integra). Cells were incubated at 37°C,
5% CO2 for 72 h and finally immunostained using the automatic




1-Wash 1× PBS No incubation/37°C
2-Fixation PFA 4% 15 min/37°C
3-Wash 3× PBS No incubation/RT
4-
Permeabilization
0.2% Triton 10 min/RT
5-Wash 3× PBS No incubation/RT












10-Wash 3× PBS No incubation/RT
11-Nuclei
staining
DAPI 1:10,000 in PBS 30 min/RT
12-Wash 3× PBS No incubation/RT
Images were acquired using the Operetta CLS High-Content Anal-
ysis system (PerkinElmer), with 40× Air/0.6 NA. 9 fields of view
with 2 slices (z =− 6.5 and −7.5) were captured per well. Alexa 488
and DAPI were excited with the 460–490 and 355–385 nm LED,
respectively.
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Mitochondrial morphology was automatically quantified using the
Harmony Analysis Software (PerkinElmer) as described in details in
Table 3 PhenoLOGIC sequence. A brightfield correction (fixed, string)
was applied to all Z-projected images. Nuclei and cells were first
segmented using the “Find Nuclei” building block on the DAPI chan-
nel and the “Find Cytoplasm” building block on the Alexa 488 chan-
nel. SER Texture analysis (Ridge, Bright, Edge, Dark, Valley, Spot) of
the mitochondrial network was then calculated. The PhenoLOGIC
supervised machine learning module of Harmony (available through
the “Select Population-Linear Classifier” building block) was used to
identify the most relevant SER textures able to segregate the three
populations (fragmented: OPA1S545R + NT siRNA, hyperfragmented:
OPA1S545R + OPA1 siRNA and rescued: OPA1S545R + DNM1L siRNA
mitochondrial morphologies). For training, ~ 800 cells per training
class (ground truth) of mitochondrial morphologies were manually
selected in each control well of each plate. The supervised machine
learning algorithm is then able to classify mitochondrial morphology
of each well into those three categories. To evaluate the quality of the
screening, we calculated the Z-score of each plate using the following
formula: Z score¼ 13ðσpþσnÞ= μp

 μnj where μp and σp are the
mean and standard deviation values of the positive control p (rescued
morphology: OPA1S545R patient fibroblasts + DNM1L siRNA) and μn
and σn those of the negative control n (fragmented morphology:
OPA1S545R patient fibroblasts + NT siRNA). The Z-score of all plates
were above 0.5 reflecting the robustness of the screening (Plate1 =
0.82, Plate2 = 0.55, Plate3 = 0.80, Plate4 = 0.79, Plate5 = 0.80,
Plate6 = 0.70).
In order to define a threshold of phenotypic rescue of mitochon-
drial morphology, we designed and deployed a univariate three-
components statistical model using R (https://www.R-project.org)
to define the siRNAs able to re-establish mitochondrial morphology
to same extent as with DNM1L siRNA. We used two models, one
designed to identify hypertubular hits data and another to identify
hyperfragmented hits among the Mitome library siRNA pools. Each
model has three components. For the rescued threshold in OPA1S545R
siRNA Mitome screen, these are the OPA1S545R NT siRNA (negative
control), the OPA1S545R DNM1L siRNA (positive control for rescued
morphology), and the OPA1S545R cells transfected with the 1,531
siRNAs of the Mitome library. For the hyperfragmented threshold in
OPA1S545R siRNA Mitome screen, these are the OPA1S545R NT siRNA
(negative control), the OPA1S545R OPA1 siRNA (positive control for
hyperfragmented morphology), and the OPA1S545R cells transfected
with the 1,531 siRNAs of the Mitome library.
Membrane potential measurement
Membrane potential was determined by FACS and live confocal
microscopy. For FACS analyses, 1 × 106 MEFs or human fibroblasts
were plated in 10 cm2 dishes and incubated 24 h with growth
media. The next day, cells were treated with 100 nM TMRE for
20 min at 37°C, 5% CO2 or with 20 µM Carbonyl Cyanide m-
chlorophenyl hydrazine (CCCP) for 30 min followed by 30-min
incubation with 100 nM TMRE + 20 µM CCCP for 20 min at 37°C,
5% CO2. Cells were washed with PBS, dissociated from the dish
with 0.05% Trypsin (Thermo Fisher Scientific), and centrifuged
5 min at 2,000 g. The cell pellet was then suspended in PBS contain-
ing SYTOX™ Blue Dead Cell Stain (diluted 1:5,000). The single-cell
fluorescence was measured using the CytoFLEX flow cytometer
(Beckman Coulter). Dead cells (SYTOX™ Blue positive cells) were
detected with the channel PB450 (450/45 BP) and discarded from
analysis. TMRE-positive cells were detected with the PE channel
(585/42 BP), and the median of TMRE intensity was used for analy-
sis. For MEFs expressing mitoYFP, YFP signal was detected using
the channel FITC (525/40 BP) and compensation between FITC and
PE channels was manually calculated.
For confocal microscopy, the genetically encoded mitochondri-
ally targeted YFP MEFs were seeded in 96well CellCarrier Ultra
imaging plates (PerkinElmer) 1 day before the measurement. The
next day, nuclei were labeled with NucBlue™ Live ReadyProbes™
Reagent (Thermo Fisher Scientific) and cells were treated with
100 nM TMRE for 20 min at 37°C, 5% CO2 or with 20 µM Carbonyl
Cyanide m-chlorophenyl hydrazine (CCCP) for 30 min followed by
30-min incubation with 100 nM TMRE + 20 µM CCCP for 20 min at
37°C, 5% CO2. Spinning disk confocal images were acquired using
the Operetta CLS High-Content microscope (PerkinElmer) with 40×
Air/0.6 NA. YFP, TMRE, and NucBlue were excited with the
460–490, 530–560, and 355–385 nm LEDs, respectively. TMRE and
YFP signal per cell were quantified using the Harmony Analysis
Software (PerkinElmer).
Cell death assay
MEFs were plated in 96- or 384-well imaging plates (CellCarrier
Ultra, PerkinElmer) and incubated at least 1 day at 37°C, 5% CO2.
The day of experiment, cells were incubated with NucBlue™ Live
ReadyProbes™ Reagent (Thermo Fisher Scientific) and Propidium
Iodide (PI, Sigma) and treated either with 4 μM Actinomycin
D + 10 µM ABT-737  20 μM qVD or 0.5 μM Staurosporine 
20 μM or 16 µM etoposide  20 μM qVD for the indicated time.
Total cells (stained by NucBlue) and dead cells (stained by PI+)
were imaged every hour for the indicated time with the Operetta
CLS High-Content microscope (PerkinElmer) at 40× Air/0.6 NA. PI
and NucBlue were excited with the 530–560 and 355–385 nm LEDs,
respectively. PI+/total cells over time were quantified using the
Harmony Analysis Software (PerkinElmer).
Stress-induced mitochondrial fission and fusion imaging
2,000 MEFs expressing mitoYFP were plated in 384-well and incu-
bated 24 h at 37°C, 5% CO2. The day of experiment, nuclei were
labeled with NucBlue™ Live ReadyProbes™ Reagent (Thermo Fisher
Scientific) for 30 min at 37°C, 5% CO2. For stress-induced fission
imaging, cells were treated with 5 μM CCCP or 16 μM 4Br-A23187
for the indicated time. For stress-induced hyperfusion imaging, cells
were treated with 10 μM CHX or 0.5 μM ActD. Nuclei (NucBlue)
and mitochondria (YFP) were imaged every hour for the indicated
time using the Operetta CLS High-Content microscope (PerkinElmer)
at 40× Air/0.6 NA. YFP and NucBlue were excited with the 460–490
and 355–385 nm LEDs, respectively. Finally, mitochondrial
morphology was quantified as described in the “Mitochondrial
morphology quantification” section.
DRP1 mitochondrial recruitment assay
2,000 MEFs expressing mitoYFP were plated in 384 well and incu-
bated 24 h at 37°C, 5% CO2.
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Cells were then fixed for 10 min with 37°C -prewarmed 4%
paraformaldehyde in PHEM Buffer (60 mM PIPES, 25 mM HEPES,
10 mM EGTA, 2 mM MgCl2, pH 7.3), permeabilized for 10 min with
0.1% Triton X-100 in PBS, and blocked overnight at 4°C with 10%
FBS in PBS. Mitochondria were stained overnight at 4°C with anti-
TOMM40 (diluted 1:1,000; ProteinTech #18409-1-AP) primary anti-
body and DRP1 with α-DLP1 primary antibody (diluted 1:1,000, BD
# 611112). Cells were incubated with anti-rabbit Alexa 568 (1:1,000;
goat anti-rabbit IgG Alexa Fluor 568; Invitrogen #A11011) and anti-
mouse Alexa A647 (1:1,000; goat anti-mouse IgG Alexa Fluor 647;
Invitrogen #A21236) for 2 h at RT. Finally, nuclei were stained for
30 min at RT with Hoechst 33342 diluted 1:10,000 in PBS. Images
were acquired using the Operetta CLS High-Content Analysis system
(PerkinElmer), with 63× Water/1.15 NA. Five fields of view with
three slices (z = 0, 0.5 and 1) were captured per well. Alexa 647,
Alexa 568, and Hoechst were excited with the 615–645, 530–560,
and 355–385 LED, respectively. Colocalization of DRP1 and
TOMM40 was evaluated using the Harmony Analysis Software
(PerkinElmer) as described in detail in Dataset EV1.
For DRP1KI MEFs, 2,000 cells were plated in 384 well, incubated
24 h at 37°C, 5% CO2 and imaged in live using the Opera Phenix
High-Content Screening system (PerkinElmer), with 63× Water/1.15
NA. 42 fields of view with three slices (z = −1, 0.5 and 0) were
captured per well. YFP (mitochondrial network) and mTurquoise2
(Drp1-mTurquoise2 tagged) were excited with the 490–515 and
435–460 lasers, respectively. Colocalization of Drp1-mTurquoise2
and YFP was evaluated using the Harmony Analysis Software
(PerkinElmer) as described in detail in Dataset EV1.
DRP1 cross-linking assay
Cells were harvested in PBS and mechanically disrupted in an ice-
cold buffer medium (containing 220 mM Mannitol, 70 mM Sucrose,
10 mM Tris-KOH, and 1 mM EDTA, pH=7,4 supplemented with
complete protease inhibitor cocktail mix [Roche]) by passing
through a 25-gage syringe (20 strokes). Nuclei and unbroken cells
were discarded by centrifugation at 700 g for 10 min at 4°C. The
post-nuclear supernatants were incubated with 10 mM 1,6-
bismaleimideohexane (BMH) or DMSO for 2 h at 4°C, and the cross-
linking reactions were stopped by the addition of 50 mM dithiothre-
itol (DTT). Proteins were quantified as described previously and
15 μg of each post-nuclear supernatants was reduced and negatively
charged with 4X Laemmli Buffer (355 mM 2-mercaptoethanol,
62.5 mM Tris–HCl pH 6.8, 10% (v/v) glycerol, 1% (w/v) SDS,
0.005% (v/v) Bromophenol Blue), were heated 5 min at 95°C, and
separated on 4–20% Mini-PROTEAN® TGX Stain-Free™ Precast gels
(Bio-Rad). Gels were then transferred to nitrocellulose membranes
with Trans-Blot® Turbo™ Transfer system (Bio-Rad). Equal protein
amount across membrane lanes was checked by Stain-free detec-
tion. Membranes were blocked for 1 h with 5% (w/v) semi-
skimmed dry milk dissolved in Tris-buffered saline Tween 0.1%
(TBST), incubated overnight at 4°C with DRP1 antibody (26187-1-
AP, ProteinTech) dissolved 1:1,000 in 2% (w/v) Bovine Serum
Albumin (BSA), 0.1% TBST. The next day membranes were incu-
bated at least 1 h in secondary antibodies conjugated to horseradish
peroxidase (HRP) at room temperature (diluted 1:10,000 in 5%
milk). Finally, membranes were incubated in Clarity™ Western ECL
Substrate (Bio-Rad) for 2 min and luminescence was detected using
the ChemiDoc® Gel Imaging System. Densitometric analysis of the
immunoblots was performed using Image Lab Software (Bio-Rad).
Mitochondrial isolation
Mitochondria were isolated as previously published (Chen et al,
2017). In brief, MEFs were infected with retroviral particles contain-
ing pMXs-3XHA-EGFP-OMP25, selected with 10 μg/ml Blasticidin
and the expression of HA-tag was verified by SDS–PAGE. The day of
experiment, ~ 30 million MEFs were collected, washed with KPBS
buffer (136 mM KCl and 10 mM KH2PO4, pH 7.25), and homoge-
nized with 25 stokes of the plunger at 1000 rpm at 4°C. Nuclei and
debris were discarded by centrifugation at 1,000 g for 2 min at 4°C.
The supernatant was collected and subjected to immunocapture
with prewashed anti-HA magnetic beads for 30 min on end-over-
end rotator 4°C. The beads were then washed three times and resus-
pended in 500 μl KPBS. 30% of the suspension beads was set aside
and used for immunoblotting. The remaining beads were store at
−150°C for the indicated analysis.
Transmission electron microscopy
Cells were grown on sapphire disks of 3 mm diameter (Engineer-
ing Office M. Wohlwend GmbH, Switzerland) previously coated
with a carbon film (McDonald et al, 2010) and frozen with a Leica
ICE high-pressure freezer machine (Leica microsystems, Austria)
with fetal calf serum as cryoprotectant. The freeze-substitution
was done in a Leica AFS2 machine in dry acetone containing 1%
osmium tetroxide, 0.1% uranyl acetate, and 5% water as previ-
ously published (Walther & Ziegler, 2002). Samples were gradually
infiltrated at RT with epoxy resin and after heat polymerization
the sapphire discs were removed from the plastic block. Sections
with a thickness of 70 nm were cut with a Leica UCT microtome
and collected on carbon, formvar-coated copper grids. Sections
were contrasted with 4% aqueous uranyl acetate and Reynolds
lead citrate. Generation of ultra-large high-resolution electron
microscopy maps was acquired using a TECNAI F20 transmission
electron microscope (FEI) with a field emission gun (FEG) as an
electron source, operated at 200 kV, and equipped with a GATAN
Ultrascan US4000 CCD camera. The SerialEM software (Mas-
tronarde, 2005; Schorb et al, 2019) was used for multi-scale
mapping as follows: Initially, a full grid map was acquired at 190×
magnification (pixel size = 551.75 nm). Middle magnification maps
at 2,500× (pixel size = 35.98 nm) were acquired in areas with
cells. Finally, high magnification maps (14,500×, pixel size =
6.194 nm) were collected at areas of interest, usually covering
large part of the cellular cytoplasm (maps consisted of 100–-
300 micrographs/pieces) where many mitochondria were
observed. Stacks of montages were displayed using the 3dmod
interface of IMOD (Kremer et al, 1996). The initial piece coordi-
nates for each micrograph are either saved at the header of the
mrc stack file by SerialEM, or in case of very large montages, at
the additional metadata file mdoc. The “Align Serial Sections/
Blend Montages” interface of IMOD (Mastronarde & Held, 2017)
was used for blending the stack of micrographs to a single large
image by calling the blendmont function of IMOD. Quantification
of cristae number and OMM/IMM perimeter was performed using
ImageJ (Rueden et al, 2017).
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Quantitative mass spectrometry of lipids
Mass spectrometric analysis was performed essentially as described
(Özbalci et al, 2013; Tatsuta, 2017). All internal standards were
purchased from Avanti Polar lipid. Lipids were extracted from
isolated pure mitochondria or whole cell pellet in the presence of
internal standards of major phospholipids (PC 17:0-20:4, PE 17:0-
20:4, PI 17:0-20:4, PS 17:0-20:4, PG 17:0-20:4, PA 15:0-18:1-d7 and
CL mix I), cholesterol (cholesterol-d7), cholesteryl esters (19:0
cholesterol ester), and TAG (D5 TAG mix I). Extraction was
performed using automated liquid handling robot (CyBio FeliX,
Analytik Jena) according to Bligh and Dyer with modifications.
Briefly, 7.5 µg mitochondria or 1 × 105 cells in 80 µl water and
internal standards (22, 17, 8.8, 6.5, 2.5, 3.0, 8, 10, 8.5, and 4 pmole
of PC 17:0-20:4, PE 17:0-20:4, PI 17:0-20:4, PS 17:0-20:4, PG 17:0-
20:4, PA 15:0-18:1-d7, CLs, cholesterol-d7, 19:0 cholesterol ester,
and TAGs, respectively) mixed with 0.3 ml of chloroform/methanol
(1:2 (v/v)) for 10 min. After addition of 0.1 ml chloroform and of
0.1 ml H2O, the sample was mixed again for 10 min, and phase
separation was induced by centrifugation (800 g, 2 min). The lower
chloroform phase was carefully transferred to a clean glass vial.
20 µl of the neutral lipid extract was taken to a glass vial, dried and
incubated in acetyl chloride/chloroform (1:5) for 2 h at 25°C under
hume hood for chemical derivatization. The upper water phase was
mixed with 20 µl 165 mM HCl and 100 µl chloroform for 10 min.
After phase separation, the lower chloroform phase was carefully
transferred to the glass vial with the rest of chloroform phase from
the first extraction. The solvent was evaporated by a gentle stream
of argon at 37°C. Lipids were dissolved in 10 mM ammonium
acetate in methanol, transferred to Twin.tec PCR plate sealed with
Thermowell sealing tape and analyzed on a QTRAP 6500 triple
quadrupole mass spectrometer (SCIEX) equipped with nano-
infusion splay device (TriVersa NanoMate with ESI-Chip type A,
Advion).
Statistical analysis
Experiments were repeated at least three times except for the follow-
ing, which were repeated two times: Fig 1C (195–2,496 cells per cell
line were analyzed per experiment), Fig 1G (879–4,154 cells per cell
line were analyzed per experiment), and Fig 4E (two independent
experiments with 18 to 52 cells analyzed per genotype). Quantita-
tive analyses were conducted blindly. Randomization of groups
(e.g., different genotypes) was performed when simultaneous, paral-
lel measurements were not performed (e.g., Oroboros, flow cytome-
try). For high-throughput measurements (e.g., mitochondrial
morphology, cell death), all groups were measured in parallel to
reduce experimental bias. Statistical analyses were performed using
GraphPad Prism 9 software. Data are presented as mean  SD or
SEM where indicated. The statistical tests used, and value of experi-
ment replicates are described in the figure legends. Tests were
considered significant at P-value < 0.05 (*P < 0.05; **P < 0.01;
***P < 0.0001; ****P < 0.0001).
Data availability
This study includes no data deposited in external repositories.
Expanded View for this article is available online.
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The paper explained
Problem
Genetic mutations in the gene Optic Atrophy 1 (OPA1) cause autoso-
mal dominant optic atrophy (DOA)—one of the most common forms
of mitochondrial disease. The majority of patients develop isolated
optic atrophy, which is a deterioration of the optic nerve, yet about
20% of patients develop more severe neurological disease (DOA+) that
cannot be fully explained by the location or nature of the disease-
causing mutation in OPA1. It has not yet been established whether
phenotypic severity can be modulated by genetic modifiers of OPA1.
Results
We developed a mitochondrial imaging and analysis pipeline that
allowed us to perform high-throughput phenotypic screening of
primary fibroblast from patients suffering from DOA+. We screened
1,531 nuclear-encoded mitochondrial genes with a bespoke siRNA
library and identified 91 genes whose depletion could suppress mito-
chondrial fragmentation in OPA1 mutant fibroblasts, including PGS1.
Impact
Our study demonstrates that mitochondrial defects cause by OPA1
deficiency are variable and can be influenced by the action of other
mitochondrial genes. The Mitome screening approach we developed
may pave the way for the functional screening of genetic modifiers
directly in the cells of patients that suffer from DOA, which could be
coupled with diagnostic applications of omics technologies already in
routine clinical use to gain insights into the variable penetrance and
expressivity of this disorder and other types of mitochondrial disease.
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